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ABSTRACT
REGULATION OF HUMAN OSTEOSARCOMA CELL DIFFERENTIATION BY
TRANSFORMING GROWTH FACTOR I3i AND la, 25-DIHYDROXYVITAMIN
THE MECHANISM OF TGFPi POTENTIATION OF 1,25D3-INDUCED

D3

ALKALINE PHOSPHATASE ACTIVITY IN HUMAN MG63 OSTEOSARCOMA
CELLS

by
XinDe Song
Transforming growth factor pi (TGFpi) is a pluripotent cytokine that works in
conjunction with other cytokines to modulate their effects on cell function. Our previous
work demonstrated that the combination of TGFpi and la,25-dihydroxyvitamin D3 had
a synergistic effect on alkaline phosphatase induction (500 to 700%) in human osteoblastic
osteosarcoma cells (MG63). The current studies focused on the molecular basis of
alkaline phosphatase induction, including the regulation of the signal transduction and
modification of la,25-dihydroxyvitamin D3 receptors (VDR). We demonstrated that
alkaline phosphatase activity was regulated at the transcription level. TGFPi at 1 ng/ml
alone had little effect on alkaline phosphatase mRNA induction and la,25-dihydroxy
vitamin D3 at 10 '8 M increased alkaline phosphatase mRNA to about 200% over the
control value. The combination of TGFPi and la,25-dihydroxyvitamin D3 significantly
increased alkaline phosphatase mRNA about 800% over the control. The peak response
was at 24 hours. Studies of the signal transduction mechanism provided evidence that the
protein kinase C pathway was involved in the alkaline phosphatase stimulation by the
combination of TGFBi and la,25-dihydroxyvitamin D3; MG63 cells express at least seven
protein kinase C isoforms and PKCy was activated by TGFBi or la,25-dihydroxyvitamin
D3 after 30 minute treatment. Studies on the VDR demonstrated that TGFpi or its
combination with la,25-dihydroxyvitamin D3 significantly increased VDR mRNA about

300% and 500% respectively over the control by 3 hours. la,25-dihydroxyvitamin D3
increased VDR mRNA about 200% by 24 hour. The VDR protein level was also
significantly elevated by the combination of TGFBi with la,25-dihydroxyvitamin D3. The
peak response at 6 hours was 300% above the control level. Our studies further showed
that a 2 hour treatment with TGF(3i and la,25-dihydroxy vitamin D3 significantly
stimulated VDR phosphorylation to 700% and 300% above the control, respectively.
When cells were treated with the combination of TGFpi and la,25-dihydroxyvitamin D3j
there was an additive effect on VDR phosphorylation to about 1000% over the control
value. Conclusions: (1) PKCy is involved in the TGFB and la, 25-dihydroxyvitamin D3
signal transduction pathway. (2) TGFP potentiates the action of la,25-dihydroxyvitamin
D3 by stimulation of VDR mRNA, VDR protein and VDR phosphorylation. These
changes further enhance the effect of la,25-dihydroxy vitamin D3 on the cellular levels of
alkaline phosphatase mRNA and alkaline phosphatase activity.
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CHAPTER ONE
I.
A.

BACKGROUND

Introduction
Osteoporosis is a disease that produces a decrease of bone mass and an increase of

bone resorption. A consequence of osteoporosis is increased susceptibility to bone
fracture. Previous studies have clearly established that the bone loss is due in part to
decreased bone formation (Kleerekoper et al., 1993). Thus, a better understanding of
bone formation could yield insight into the cause and treatment of osteoporosis. Bone
formation involves two processes: osteoblast differentiation and proliferation. Proliferation
has been studied extensively while the molecular mechanisms regulating cell differentiation
have not been well defined. Alkaline phosphatase (ALP) increases during osteoblast
differentiation and this increase is utilized as a marker for osteoblast differentiation. Two
regulatory factors, transforming growth factor Bi (TGFB1) and la, 25-dihydroxyvitamin
D3 (1,25D3), together produce the largest stimulation of ALP activity observed to date as
much as 6 fold in normal human bone cells (Wergedal et al., 1992) and 50 fold in the
human osteosarcoma cell line MG63 (Bonewald et al., 1992). This remarkable increase in
the ALP activity is due to a synergism between the individual effects of the two factors.
More specifically the synergism of ALP induction is caused by a TGFBi modification of
the 1,25D3 signal pathway because the synergism was induced by sequential addition of
TGFBi and then 1,25D3) but not vice versa. The current study is focused on the
mechanism of the synergistic induction of ALP by TGFBi and 1,25D3.

l
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B.

Transforming growth factor B
1. Source and classification
Transforming growth factor Bj (TGF(3i) is a stable multifunctional cytokine. It is a

25 kDa protein which is a disulfide-linked dimer of two usually identical chains and
originally identified as a growth factor that induced the growth of normal rodent
fibroblasts in soft agar. TGFpi has been found in the highest concentration in human
platelets and mammalian bone and is also produced by most tissues in smaller amounts
(Finkelman et al., 1990).
TGFpi belongs to a family of structurally related proteins. The TGFBi family
includes a number of factors distantly related to TGF(3i, including the activins, inhibins and
bone morphogenetic proteins (BMPs) (30-40% sequence identity), and a number of more
closely related proteins (70-80% sequence identity) designated as TGFB 2,3,4, and TGFp5
(Sporn et al., 1987, 1990, and 1992). These proteins have important functions in the
regulation of cellular proliferation and differentiation. The first form of TGFB to be
described, now designated TGFBi, was originally purified from human platelets, and is the
best characterized isoform. TGFB2 and TGFB3 have also been identified in mammalian
tissues and cells. The three TGFB isoforms are similar in their biological activities,
although in hematopoietic progenitor cells and endothelial cells, TGF(3i and TGFp3 are
more potent than TGFp2 (Cheifetz et al., 1990). TGFB4 and TGFB5 have been cloned
from chicken and frog cDNA libraries, but the related forms have not been found in
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mammals. The current studies have used TGFpi. Preliminary studies have shown that
TGFp2 produces the same effects as TGFPi on bone cells.
2. TGFpi activation
TGFP is synthesized and secreted by most cell types as a latent high molecular
weight complex (Miyazono et al., 1991). This large precursor peptide has 390 amino acid
residues; a dimer of the C-terminal 112 amino acid peptide forms the active TGFpi.
Sequencing of the cDNAs for the five isoforms of TGFB indicates that each protein is
initially synthesized as part of a larger precursor molecule containing the mature form of
TGFB isoforms at its C-terminus (Derynck et al., 1988; Kondaiah et al., 1990). The
latent TGFPi is composed of the active TGFpi dimer and a dimer of the N-terminal part
of the TGFpi precursor. Proteolytic cleavage of the precursor just after a stretch of four
basic amino acids is mediated by a protease (Barr et al., 1991). The two portions of the
precursor remain together following cleavage and are secreted in a biologically inactive
form. At this stage, the complex consists of the dimers of the precursor remainder
designated as the TGFPi latency associated peptide (Bi-LAP) and the mature TGFp
Latent TGFPi purified from human or rat platelets is composed of three different
components, i.e. mature TGFPi, Bi-LAP and a third molecule which is called the latent
TGFp binding protein (LTBP) (Miyazono et al., 1988; Okada et al., 1989) (Figure 1).
The latent TGFB complex with LTBP has been called the large latent TGFB complex and
the molecules without LTBP have been called the small latent TGFB complex. It was
reported that human LTBP is synthesized as a protein with 1394 amino acid residues and
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more than 60% of its structure is composed of 16 cysteine-rich repeat sequences which
share homology with epidermal growth factor (EGF). The EGF-like repeat is observed in
different proteins, such as growth factors, extracellular matrix proteins and cell surface
receptors (Apella et al., 1988). It has been suggested that EGF-like domains mediate
homophilic and heterophilic protein-protein interactions.
Mature TGFpi can be released from the complex in an active form in vitro by a
variety of treatments, most commonly by acidification ( Spom et al., 1993). Although a
number of intriguing observations have been reported and a variety of mechanisms
proposed for its activation, in vivo activation of latent TGFBs is currently unknown.
Some observations suggest that proteolytic cleavage of the LAP can cause the release of
active TCFfb from the latent complex.
3. TGFfii signal transduction pathways
TGF(3i as well as several other agents have been found to transiently alter EGF
binding in a noncompetitive fashion and this effect has been termed receptor
transmodulation (King et al., 1982; Olashaw et al., 1987). Significant evidence has been
obtained implicating a role for protein kinase C (PKC) in this form of regulation.
Treatment of cells with 4P-phorbol 12-myristate 13-acetate (PMA) which is phorbol ester,
and subsequent activation of PKC, has been shown to result in the transmodulation of the
binding capacity, localization and activity of receptors for EGF, b-Fibroblast growth
factor (bFGF), Platelet-Derived growth factors (PDGF), transferrin, insulin, tumor
necrosis factor a, insulin-like growth factor II, interleukins 1 and 2 (Backer et al.,
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1991). In most cases, transmodulation has been associated with direct serine and
threonine phosphorylation of these receptors by PKC. It was suggested that the activation
of PKC by TGFBi might regulate EGF receptor function through an indirect pathway
involving serine or threonine phosphorylation of an unknown protein (Newman et al.,
1993). Additionally, TGFPi receptors have recently been shown to comprise a novel
family of serine/threonine kinases that phosphorylate a serior of signaling proteins
(Massague et al., 1992). Thus, TGFpi could also conceivably modulate EGF receptor
function through a PKC-independent phosphorylation pathway. Evidence for a role of
PKC in the cellular response to TGFBi has also been suggested by studies with vascular
cells and chondrocytes (Markovac et al., 1988; Wrenn et al., 1993). These studies
showed a rapid PKC activation by TGFpi and this PKC response was related to cell
function regulation. The ability of phorbol esters and TGFpi to regulate the activity of
so many different types of cell surface receptors suggests that the activation of PKC or
an intrinsic serine/threonine kinase activity may play an important role in cell function
regulation ( Houslay et al., 1991).
4. TGFPi receptors
The actions of TGFPi are mediated by binding to cell surface receptors. Crosslinking studies with 131I-labeled TGFPi show that most cells have three size classes of
TGFPi binding proteins. These are designated Type I (53 kDa), Type II (70-85 kDa) and
Type III (250-350 kDa) (Segarini et al., 1991; Massague et al., 1990). The genes for the
three types of TGFpi receptors have been cloned and studied. The type III receptor has
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been identified as a chondroitin/heparin sulfate proteoglycan (betaglycan) that exists in
both membrane-bound and soluble forms (Cheifetz et al., 1989; Andres et al., 1989).
Recent work regarding biological responses to TGFpi -resistant mutants and restoration
of sensitivity by complementation has shown that Type I and Type II receptors are
involved in mediation of biological responses to TGFB and that these two receptors
interact with each other (Boyd et al., 1989; Laiho et al., 1991). The type III receptor is
apparently not capable of mediating the signal transduction (Boyd et al., 1989). A model
for the interaction of TGF(3i with its receptors is emerging. In this model, TGFpi binds to
betaglycan (type III receptor) on the cell surface and is presented to the type II receptor
with the subsequent formation of a high-affinity complex consisting of TGFpi, type II and
type III receptors. The betaglycan is then displaced from this complex by the type I
receptor. This high affinity complex of TGFPi, type II and type I receptors initiates
signal transduction.

This model suggests an explanation for equal activities of the TGFpi

isoforms despite differential affinities for the type I and type II receptors and for the
observed differential responses of some cells to TGFpi and TGFp2. In the current study,
TGFPi presumably acts on cells through these receptors, but this aspect has not been
studied. The activation of TGFpi receptors is required the formation of above TGFpi
complex in which the serine/threonine kinases on introcellular domain of type II receptor
can phosphorylate the serine/threonine residues of type I receptor. Phosphorylation of the
type I receptor correlates with activation of its kinase activity and is required for initiation
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of signal transduction. This event will further activate an unknown kinase cascade and
transduce the TGF(3i signals.
5. TGFB biological activity
TGFPi has a wide range of biological activities. Nearly all cells have surface
receptors and respond to TGF(3i. The nature of the response depends on a variety of
factors, including the cell type, growth conditions, the state of cell differentiation as well
as the presence of other growth factors (Spom et al., 1993). The effect of TGFJ3i on
proliferation and differentiation may be stimulatory or inhibitory, depending on the
conditions. TGFpi is an important mediator controlling the formation of extracellular
matrix and a potent inhibitor of the myogenesis of both skeletal and cardiac muscle cells
in vitro and presumably in vivo (Sporn et al., 1992; Sporn et al., 1993). TGFPi regulates
osteoblast proliferation and differentiation and also plays an important role in bone
remodeling (Bonewald et al., 1990). It also appears to regulate osteoblast function by
increasing alkaline phosphatase activity and enhancing collagen production, both of which
are osteoblast cell differentiation markers (Bonewald et al., 1992; Wergedal et al, 1992).
It is suggested that TGFPi works in conjunction with other cytokines and hormones to
modulate their effects (Sporn et al., 1986). The action of TGFPi appears to be critically
regulated at several steps, including the binding to different types of receptors,
activation of different signaling pathways and phosphorylation of different cytosolic and
nuclear substrates. All these effects depend on cell density, differentiation stage, and
serum concentration. In vitro, TGFpi has been shown to stimulate osteoblasts and to
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inhibit osteoclasts. Thus, it is an important molecule for bone remodeling (Mundy et al.,
1989). TGFBi has also been implicated in the morphogenesis and remodeling of
mesenchymal tissues during embryological development (Heine et al., 1987).
C.

la, 25-dihydroxyvitamin D3
1. Structure, synthesis and metabolism
The most abundant form of vitamin D is vitamin D3, also refered to as

cholecalciferol. Vitamin D3 is not truly a vitamin and is not required in the diet. Instead,
it is synthesized from 7-dehydrocholesterol, an intermediate in cholesterol biosynthesis.
It is more accurate to think of vitamin D3 as a prohormone, because it is converted to a
metabolite that acts analogously to a steroid hormone. The vitamin D3 structure, synthesis
and metabolism are shown in Figures 2 and 3. Generally, the vitamin D3 structure
contains three cyclohexane rings — A, B, C with another five membered D ring and a side
chain. The precursor of vitamin D3 is cyclopentanoperhydrophenanthrene which comes
from cholesterol or isoprenoids. The classification of vitamin D3 as a seco-steroid means
that one of the cyclop entanoperhydrophenanthrene ring structures (B ring) is broken and
the B ring forms a conjugated triene (Mathews et al., 1990).
Vitamin D3 is synthesized from 7-dehydrocholesterol through ultraviolet photolysis
and the product in skin cells is named as cholecalciferol. It undergoes two successive
hydroxylations, each catalyzed by a mixed-fiinction oxidase. The first reaction, at carbon
25, involves a microsomal enzyme named 25-hydroxylase in the liver. 25-hydroxy
cholecalciferol is the most abundant circulating form of the vitamin D and is transported to
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the kidney, where a mitochondrial enzyme hydroxylates it at the number 1 carbon. The
the enzyme named 25(OH)D3-la-hydroxylase catalyzes the second reaction, by which the
product is la, 25-dihydroxyvitamin D3 (1,25D3). This product is the most powerful active
form of vitamin D3. The 25 (OH)D3-la-hydroxylase is the target of intricate regulatory
controls that are dictated mainly by blood calcium and phosphorus levels (Garabedian et
al., 1972). For example, lower serum calcium levels stimulate the release of parathyroid
hormone (PTH), which in turn acts on the la-hydroxylase to increase 1,25D3 production.
1,25D3 also acts on the 25(OH)D3 - la-hydroxylase in a classical feedback mechanism to
down-regulate the enzyme as well as stimulate a 24-hydroxylase activity which converts
the 25-hydroxyvitamin D3 into 24, 25-dihydroxyvitamin D3, a less active form of vitamin
D3. Eventually vitamin D3 is degraded to calcitroic acid for excretion in the urine.

1,25D3

can be synthesized in other tissue cells besides the kidney (Weisman et al., 1978). The
skeleton was reported as a site for 1,25D3 production (Howard et al., 1981). Now it is
unclear whether the la-hydroxylase is located in mitochondria or microsomes of bone
cells (Hollis et al., 1989).
2. Vitamin D receptor
(1) Structure
The classification of vitamin D3 receptors (VDR) as an authentic member of the
steroid/thyroid superfamily of hormone receptors has been established (Haussler et al.,
1988). VDR can be divided into two discrete, functionally independent subdomains; one
is involved in DNA interactions and the other binds to its ligand, 1,25D3 (Allegretto et al.,
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1987a). Sequence comparison of the VDR cDNA with other nuclear receptors for steroid
and thyroid hormones shows three regions of significant homology, which were originally
designated Cl, C2, and C3. Cl domain on N-terminal contains two zinc finger motifs.
This 70-amino acid domain is rich in cysteine, lysine, and arginine residues and is
responsible for the interaction with specific DNA sequence elements (VDRE). It has been
termed the DNA binding domain (DBD). The C-terminal domain of VDR is responsible
for its high affinity interaction with 1,25D3 and is designated the ligand binding domain
(LBD) (Allegretto et al., 1987a).
The DBD is located in the N-terminal portion of the VDR (Allegretto et al.,
1987b). McDonnel et al. (1989) further demonstrated that amino acid positions 1 through
113 contain the site for DNA binding or transcriptional activation potential of the VDR.
It has been reported that there are 9 cysteine residues within the DBD and that 8 of these
9 are proposed to tetrahedrally coordinate two zinc atoms to form the so called zinc finger
DNA binding motifs (Sone et al., 1991a). The key amino acid residues of the DBD that
mediate the selective DNA binding are within an oc-helical region at the base of the first
zinc finger motif.

Specifically, three amino acid residues (glutamic acid and two glycine

residues) in this region may be involved in target sequence recognition (Danielson et al.,
1989; Mader et al., 1989). The three-dimensional structural analysis of the purified
DBDs for the retinoic acid receptor (RAR), retinoic X receptor (RXR), and VDR
demonstrated that the DBD of these receptors all fold into two oc-helices in the carboxyl
terminal portion of the each zinc finger, to form a single domain. The first a-helix in the
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amino terminal finger lies across the major groove of DNA, making specific contacts with
the DNA binding site. The second a-helix folds across the first in a perpendicular
arrangement. The DBD is also rich in positively charged amino acid residues (i.e. lysine
and arginine) which form favorable electrostatic interactions with the negatively charged
phosphate backbone of the DNA helix.
The LBD is located in the C-terminal portion of the VDR. Ligands like 1,25D3
bind avidly to the LBD with a dissociation constant on the order of 10 '10 M ( Brumbaugh
et al., 1974; Wecksler et al., 1980). 1,25D3 binds to the LBD with approximately 100
fold stronger affinity than does 25(OH)D3 and the nonhydroxylated parent vitamin D3
compound does not bind at all to the VDR. The location of the LBD in the C-terminal
region was demonstrated biochemically with limited proteolysis of intact VDR (Allegretto
et al., 1987b). Both limited carboxypeptidase A digestion and deletion mutation
experiments showed that the region for binding the 1,25D3 ligand is from the amino acid
residues 200 to 300 of the C-terminal region (McDonnell et al., 1989; Nakajima et al.,
1993b).
In addition to hormone binding, the LBD is also involved in other aspects of
receptor function, including protein-protein interactions. It was suggested that there is a
common structural motif, designated as heptad repeats, located throughout the LBD of
several receptors, including the VDR (Forman et al., 1990). The heptad repeat contains
leucine or other hydrophobic amino acid residues at positions 1 to 8 of the repeat. The
hydrophobic amino acids or charged amino acids with hydrophobic side chains would
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form a hydrophobic surface along one side of the helix that could act as a dimerization
interface to form dimers between VDR and other receptor auxiliary factors (Nakajima et
al., 1993a).
Another region for protein-protein interaction is the Hinge region located between
the LED and the DBD. Little is known about the structural aspects of this region of the
VDR, but it is apparent that the domain is highly immunogenic (Pike et al., 1988). Sone
et al (1991a) reported that an internal deletion of residues 103 to 114 generated a mutant
VDR that did not bind to the specific DNA sequence of VDRE. Perhaps this region of the
VDR serves as a protein-protein interaction domain and is necessary for VDR to bind to
DNA.
(2) VDR function and interaction with VDRE
VDR is a ligand-dependent transcription factor that is capable of recognizing and
binding to cis-acting hormone response elements (VDRE) in promoter regions of
appropriate target genes. This specific protein-DNA interaction initiates a mechanism that
modulates RNA polymerase Il-dependent transcriptional activation (Pan et al., 1987). It
was demonstrated that VDR binds to the osteocalcin VDRE, not as a homodimer, but as a
heterodimeric complex in association with another nuclear factor (Figure 4) (Liao et al.,
1990). This nuclear factor has been designated as nuclear accessory factor (NAF) or
receptor auxiliary factor (RAF). The biochemical properties of the VDR auxiliary factor
were recently characterized. RAF is a widely expressed protein which has a molecular
weight of approximately 55 kDa and binds with high affinity to the VDR (Sone et al.,
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1991b). The estimated equilibrium dissociation constant for the VDR-RAF-VDRE
complex was approximately 0.24 nM, indicating a rather tight association of the
heterodimer formation. Finally, the in vitro interaction of VDR-RAF-VDRE is markedly
enhanced by the addition of 1,25D3, suggesting a direct role of the hormone in either
hetero dimer formation or in the interaction of the hetero dimer with the VDRE.
The dimerization of VDR and retinoid X receptor (RXRs) provides another
example for VDR-mediated gene transactivation (Figure 4). Because 9-cis retinoic acid is
the ligand for RXR and more potent than all-trans retinoic acid in RXR-mediated
transactivation (Heyman et al., 1992; Levin et al., 1992), the putative role of RXR in
VDR-mediated transcription is that 9-cis retinoic acid can interact with 1,25D3 on VDR
function by binding to RXR and promoting dimerization of both VDR and RXR. Briefly,
hetero dimerization between VDR and RXRs or RAFs may provide a means of generating
increased diversity of transcriptional controls with respect to vitamin D-dependent
pathways. Such a mechanism would generate a much higher degree of diversity and
specificity in 1,25D3 -controlled gene expression.
(3) VDR gene and regulation
The human VDR (hVDR) gene is located on the region 12ql3-14 of chromosome
12 (Faraco et al., 1989). The hVDR genomic DNA is approximately 45 kb long and
consists of 9 coding exons interrupted by introns ranging from 0.2 to 13 kb. Full length
hVDR cDNA has been isolated. It is 4605 bp long and contains a 115 bp noncoding
leader sequence, a 1281 bp open reading frame and a 3209 bp 3’ non-coding tail
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(McDonell et al., 1987; Baker et al., 1988). It codes one RNA transcript about 4.6 kb
which encodes a 427 amino acid residue protein with a calculated molecular weight of
approximately 48 kDa, agreeing well with the protein data. Further details on the VDR
gene promoter region and structure as well as sequence have not been reported. However,
several factors affect VDR gene expression. These included dexamethasone, PTH,
cAMP, TGFp and 1,25D3 itself (Pan et al., 1987; Chen et al., 1985; Chen et al.,
1986a). The isolation of VDR cDNA and its classification as a member of the superfamily
of steroid receptors provides the tools for understanding the effects of 1,25D3 as well as
other hormones and growth factors on VDR gene expression.
3. Vitamin D responsive element
The vitamin D responsive element (VDRE) is one of specific DNA elements in the
promoter regions of 1,25D3 hormone responsive genes which specifically interacts with
VDR and has been described in the osteocalcin (BGP) and osteopontin genes of human
and rat (Demay et al., 1990; Terpening et al., 1991). VDRE consists of imperfect direct
hexanucleotide repeats separated by a three-nucleotide spacer: GGGTGA ACG
GGGGCA (human BGP). This direct repeat is analogous to a DNA segments that
mediates retinoic acid (RAREs) and thyroid hormone responsiveness (TREs). In general,
VDR, thyroid hormone receptor (TR) and retinoic acid receptor (RAR) recognize similar
direct repeat sequences, but with differing spacer regions of 3,4, and 5 nucleotides,
respectively. This phenomenon was termed as the “ 3-4-5 rule”. So the spacer region
plays a major role in determining the specificity for hormone selectivity. Besides the
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VDRE, which is activated by 1,25D3, another kind of VDRE that mediates 1,25D3dependent transcriptional repression has been reported (Demay et al., 1992). This
element confers l,25D3-dependent suppression on heterologous promoters and it
functions in a cell-type specific manner. Structurally, the negative VDRE is different
from the positive VDRE, but it still needs to be determined how these structural
differences are translated through the VDR or other factors to affect transcriptional
regulation.
4. Biological activity
There is now extensive evidence suggesting that the steroid hormone 1,25D3
generates biological responses by genomic as well as nongenomic mechanisms (Norman et
al., 1992; Baran et al., 1991). The genomic effect of 1,25D3 is mediated through its
nuclear receptor, nVDR to affect cell differentiation and proliferation. The nongenomic
effect of 1,25D3 is mediated by its membrane receptor which in turn activates PKC and
mitogen-activated protein kinase (MAPk) pathways (Slater et al., 1995), as well as by
stimulating the opening of calcium channels and increasing membrane calcium influx
(Bouillon et al., 1995). The classical targets of 1,25D3 are the intestine, bone, and kidney
by which 1,25D3 plays a role on maintaining mineral homeostasis, particularly with
respect to inorganic calcium and phosphate. Now we know that 1,25D3 also exerts
biological effects on a number of tissues and cells such as the immune system,
hemopoietic and others ( Reichel et al., 1989). 1,25D3 has been shown to stimulate
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osteoblast differentiation, promote the differentiation of promonocytes into monocytes
and enhance other cellular differentiation (Bouillon et al., 1995).
(1) Genomic effect
Bone is a major physiologic site for the action of 1,25D3. 1,25D3 regulates
principal events associated with bone formation and resorption. For example, 1,25D3 acts
on osteoblasts to affect both anabolic and catabolic components of bone homeostasis
(Darwish et al., 1993). 1,25D3 regulates transcription of more than 60 genes including
several osteoblast related genes, such as BGP (Demay et al., 1989), osteopontin (Noda et
al., 1990), otl(I) procollagen (Lichtler et al., 1989) and its own receptor (Chen et al.,
1986b). 1,25D3 also regulates several oncogenes, such as c-jun, c-fos and c-myc. Figure 5
shows how 1,25D3 exerts its genomic effect through its nuclear receptor and how this
steroid-receptor complex interacts with the VDRE. The effects on transcription can be
either positive or negative transcriptional activation (Haussler et al., 1988; Ozono et al.,
1991; Carson-Jurica et al., 1990).
(2) Nongenomic effect
Rapid nongenomic actions of 1,25D3 have been observed both at the cellular (e.g.
calcium transport across a tissue) and subcellular membrane calcium transport level,
particularly in intestine, liver cells and osteoblast ROS 17/2.8 cells (Cafifrey et al., 1989).
In the above tissues and cells, 1,25D3 induced a rapid Ca++ transmembrane influx that was
mediated by a new membrane protein, named transcaltachia (Nemere et al., 1984). Both
the chick intestine and ROS 17/2.8 cells were demonstrated to respond to 1,25D3 within
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several minutes with evidence for involvement of both protein kinase C and a voltage
gated Ca++ channel (Cafffey et al., et al: 1989). It has been proposed that there is a
1,25D3 membrane receptor with different ligand binding properties from the it nuclear
receptor (VDR).

VDR was recently separated and partially purified from the chick

intestinal enterocyte basal lateral membranes and was shown to be a 60 kd protein . The
function, regulation and expression of mVDR are currently under investigated.

D.

PKC mediated signal transduction pathway
Signals are transduced across the cytoplasmic membrane through highly elaborate

network of molecular events which are initiated by stimulation of receptors and further
driven by kinase cascades. Protein kinase C (PKC) is a serine/threonine kinase that
mediates a major signal transduction pathway involving regulation of cell proliferation and
differentiation. PKCs are activated by Ca++, diacylglycerol (DAG) and phospholipid
(Nishizuka et al., 1992; Asaoka et al., 1992). Because of these requirements, PKC is
generally thought to be activated in the cell by signal transduction cascades that produce
DAG, such as activation of phospholipase C. PKC is also thought to be the major
receptor of tumor-promoting phorbol ester (PMA), which activates the kinase in vitro in a
manner very similar to DAG (Gschwendt et al., 1991; Bell et al., 1991).
1. Structure and Isoforms
It is clear that many closely related PKC isotypes exist in cells. Based on cofactor
dependence and responsiveness to phospholipid metabolites in vitro, PKC can be further
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classified as cPKC (Ca++-dependent PKCot, (31, (32, and y), which show typical
characteristics of the classical PKC (Nishizuka et al., 1992), nPKC (Novel PKC5, 8, 0 and
r|) and aPKC (atypical PKC^, and i) subfamilies. Neither nPKC nor aPKC require Ca++ .
aPKC does not require DAG or phorbol ester for the activation (Nakamura et al., 1994).
The different activator requirements of PKC isoforms indicate that the PKC signaling
pathways may be not restricted to those leading to the generation of DAG, but might also
involve other activators such as PI 3 kinase or MAP kinase to mediate different cell
responses (Asaoka et al., 1992).
Figure 6 shows the structure of the PKC’s subfamily. The regulatory domain on
the N-terminal of the cPKC contains two conserved regions, Cl and C2, that play a
critical role in the regulation of PKC activity. The Cl region is comprised of a
pseudosubstrate sequence followed by two tandem repeats of a cysteine-rich zinc finger
motif. This zinc finger motif is responsible for DAG and phorbol ester binding (Quest et
al., 1994; Ono et al., 1989a). The nPKC and aPKC isoforms lack the C2 domain which is
needed for Ca++ binding. The catalytic domain of the C-terminal of the PKC contains
two additional highly conserved regions, C3 and C4, which are responsible for ATP and
protein substrate binding respectively (Dekker et al., 1994).
In most cell types, only a certain subset of PKC isoforms are present (Hug et al.,
1993). Such differences in distribution suggest a divergence in function between PKC
isotypes. PKC subcellular distribution also shows differential characteristics. Differences
in subcellular localization of the various PKC Isoforms have also been reported. This
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compartmentalization of PKC isoforms appears to be dynamic and can be changed in a
manner that is dependent on the activation state of the cell. It has been reported that
PKC(3 translocated to the nucleus under the effect of 1,25D3 in renal epithelial cells which
implicated the function of PKC P in transduction of the signal and in gene regulation
(Simboli-Campbell et al., 1994).
2. Activation and regulation of PKC
DAG is an in vivo activator of PKC and is generated by the hydrolysis of
phosphatidylinositol 4, 5-bisphosphate (PIP2) as a result of phospholipase C activation
(Figure 7). The DAG molecule disappears rapidly due to the action of DAG kinase (Ford
et al., 1990; Lee et al., 1991), but frequently increases again after a lag which is called
“sustained elevation of DAG” observed in response to various long-acting signals such as
the presence of growth factors. Only sustained elevation of DAG is pre-requisite for
long-term responses such as cell growth and differentiation (Asaoka et al., 1992;
Nishizuka 1995). Multiple isoforms of phospholipase C (PLC) have been identified and
more than one mechanism is known to activate PLC to generate DAG (Dennis et al.,
1991; Rhee et al., 1993). PLCy can be activated by receptor and non-receptor tyrosine
kinases (Rhee et al., 1992; Nishibe et al., 1990),

whereas PLCp is activated by the

a-subunit of G protein (Taylor et al., 1991; Smrcka et al., 1991).
By conventional concept, PKC activation shows a rapid translocation of the
enzyme from its inactive form in the cytosol to the activated state in the membrane (Abou-
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Samra et al., 1989). PKC activation without translocation between compartments has
also been reported (Grabarek et al., 1993; Ryves et al., 1991).
The physiological significance of the existence of multiple PKC isoforms remains
to be elucidated. Probably, the members of PKC family respond differently to various
combinations of Ca++, phosphatidylserine (PS), DAG, and other membrane phospholipid
metabolites, including free fatty acids and lysophospholipids. Thus, the patterns of PKC
isoform activation may vary in extent, duration, and intracellular localization. It is difficult
to assess the exact consequence of the activation of a certain PKC isoform within the
cell. One way is to overexpress a PKC isoform and examine its biological effects. By
overexpressing PKCs in mouse myeloid progenitor cells, it is clear that PKCoc and 5, but
not PKCP, e and rj can participate in myeloid differentiation induced by PMA (Mischak et
al., 1993). Using the dominant negative mutants of PKC provides another way to assess
PKC functional involvement in signal transduction processes. Overexpression of such
kinase mutants might lead to disruption of the signaling pathway.
3. Crosstalk between the PKC and other pathways
The diverse roles of PKC in cell to cell communication and cellular response was
anticipated. PKC and the other protein kinase cascades play essential roles in cellular
regulation (Blenis et al., 1993; Nishida et al., 1993). The aPKC isoform was shown to
phosphorylate and activate Raf-1 directly (Kolch et al., 1993), which in turn activates
MAP-kinase (Kyriakis et al., 1992; Dent et al., 1992). Prolonged activation of MAP
kinase with phorbol esters in the CHO cell line was observed by over-expressing the
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8PKC (Gaudry et al., 1993). The ocPKC and 5PKC Isofonns are distributed widely in all
tissue and cell types examined so far, implying their important roles in intracellular
signaling pathways (Nishizuka et al., 1992). It is also known that the treatment of cells
with a phorbol ester and DAG induced the activation of protein tyrosine kinase (Gilmore
et al., 1983; Gaudry et al., 1993) and thus activated phosphorylation of EGF receptors.
The PKC pathway also interacts at the cellular level with the cAMP-protein kinase A
(PKA) pathway. PKA exerts an inhibitory effect at the level of Raf-1 by phosphorylating
specific residues of the Raf-1 protein (Cook et al., 1993). This cross-talk may provide a
biochemical basis for the counteraction by cAMP of the cellular responses provoked by
the PKC signaling pathway which occurs in many tissues and cells (Nishizuka et al.,
1986).
The PKC pathway also converges with other signaling pathways at the point of
nuclear protein factors which are necessary for gene expression (Jain et al, 1993). The
activation of these nuclear factors appears to be mediated through the simultaneous
actions of PKC, MAP-kinase, and calmodulin-dependent protein kinase (Nakajima et al.,
1993b; Wegner et al., 1992). Because PKC plays an important role in mediating many
growth factor functions, it is important to explore the possible involvement of PKC in
TGFpi and 1,25D3 action and study how the PKC pathway is regulated in both TGFp
and 1,25D3 function.
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E.

Osteoblast differentiation and MG63 cells
Bone formation can be arbitrarily divided into two categories: (i) proliferation, a

process in which preosteoblasts and osteoblasts (OB) multiply to increase their number;
and (ii) differentiation, a process in which OB mature and become active bone forming
cells. The former is very well studied so far but little is known about the regulation of
human OB differentiation. Control of osteoblast differentiation can be characterized by
several processes, including receptor-activated signaling cascades, namely, PKA
pathway, PKC pathway, receptor serine/threonine kinase pathways and vitamin D3
receptor-mediated pathways. These events regulate mature osteoblast specific gene
expression. Osteoblast differentiation can be assessed by several biological markers such
as skeletal alkaline phosphatase, type I collagen, BGP, and osteopontin. Of these,
alkaline phosphatase has been recognized not only as an important cell surface marker of
mature OB but also as an index of bone formation.
MG63 cells are a human osteoblastic osteosarcoma cell line which possesses
normal osteoblast characteristics (Bonewald et al. 1992). The advantage of using this
model is that MG63 cells express a low basal levels of alkaline phosphatase activity and
thus have a stronger ALP activity induction in response to 1,25D3. When MG63 cells are
pretreated with TGFPi, 1,25D3 can cause a synergistic (20-70 fold) increase of alkaline
phosphatase activity. This synergistic response makes the MG63 cells an excellent model
for studying osteoblastic differentiation.
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F.

Alkaline phosphatase
Alkaline phosphatases [orthophosphoric-monoester phosphohydrolase (alkaline

optimum), EC 3.1.3.1, (ALP)] are phosphatidylinositol-linked membrane glycoproteins
that catalyze the hydrolysis of monophosphate esters at alkaline pH (McComb et al., 1979;
Harris et al., 1982). ALP is present in almost all tissues (McComb et al., 1979). In the
humans, four isozymes (liver/bone/kidney type, intestinal type, placental type and
placental-like type) have been characterized. The liver/bone/kidney isozyme (LBK ALP)
is expressed in the liver, bone, kidney and most other tissues but at a much higher level in
bone-forming osteoblastic cells (Goldstein et al., 1982). The intestinal ALP, placental
ALP and placental-like ALP isozymes are tissue-specific and expressed primarily in the
tissues for which they are named (Stigbrand et al., 1984).
1. Biological function of LBK ALP
Bone ALP is a dimer with a molecular weight of about 67 kDa for each monomer
(Stigbrand et al., 1984). It was also reported that bone ALP is a tetramer in its native
membrane-bound form with a molecular weight about 200-400 kDa (Feffe et al., 1988;
Nakamura et al., 1988). The LBK ALP is likely involved in bone mineralization (Wuthier
et al., 1985). This is supported by the facts that (1) osteoblasts normally express very high
levels of LBK ALP activity (Harris et al., 1982; Weiss et al., 1988b); (2) the patients with
the hypophosphatasia express very low levels of LBK ALP activity accompanied by poor
bone mineralization (Rasmussen et al., 1983; Whyte et al., 1987). It is now clear that
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hypophosphatasia is an autosomal recessive disease in which mutated ALP genes have
been identified in the patients (Weiss et al., 1989; Weiss et al, 1988a).
The real biochemical function of LBK ALP has not been established but four
possible functions in the mineralization process have been attributed to this enzyme
(Register et al., 1986). They are : (1) hydrolysis of organic phosphate esters resulting
in high local phosphate concentration, which facilitates precipitation of calcium
phosphate; (2) destruction of physiological crystal growth inhibitors, such as inorganic
pyrophosphate and ATP through its hydrolase activity; (3) action as a phosphate
transporter; and (4) active transport of Ca++ or Pi through its ATPase activity. Generally,
ALP activity is accepted as a bone cell maturation and differentiation marker, but its real
role involving bone cell differentiation has still not been established.
2. LBK ALP gene
The gene coding for the LBK ALP is located at chromosome 1, bands p34-p36
(Smith et al., 1988).

The entire gene is comprised of at least 50 kb of DNA and consists

of 12 exons with the coding sequence beginning within the second exon (Figure 8) (Weiss
et al., 1988b). Exons 2 to 12 are 25 kb long. The intron between exon 1 and 2 is at least
an additional 25 kb and has not been completely sequenced. In human, two alternative
non-coding leader exons have been identified in the LBK ALP gene and named bone-type
exon IB (Kishi et al., 1989) and liver-type exon 1L (Matsuura et al., 1990). They control
the expression of two types of ALP transcripts.
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The presence of two leader exons for the transcripts of the ALP gene suggests
that the gene has two promoters and may be regulated by independent mechanisms. It
was demonstrated that bone-type mRNA and liver-type mRNA for the ALP gene were
dominantly expressed in osteosarcoma cells and liver respectively (Matsuura et al., 1990).
It is suggested that these two promoters are regulated and expressed differently. Because
the 5’-flanking region of neither of the two leader exons is fully sequenced, it is difficult
to postulate the mechanism of ALP gene regulation by growth factors or hormones. Sato
et al (1994) reported the presence of a TATA box, four SP-1 binding sites and a putative
RARE-RXRE (AGGTCAGAGCCCA) sequence in the bone-type exon IB promoter
region. It is reported that the ALP gene expression is modulated by various biological
agents, such as glucocorticoids, 1,25D3, and parathyroid hormone (Rodan et al., 1984a).
1,25D3 is a strong ALP activator in osteoblasts, but there is no VDRE sequence identified
so far in the partially sequenced ALP promoter regions. Because VDR and RXR are
closely related and form heterodimers on gene regulation and activation, it is possible that
there is a VDRE next to the RXRE DNA element and that the VDR-RXR hetero dimer
function as a transcription activator of the ALP gene.

G.

Clinical significance of present study
Osteoporosis is a disease characterized by low bone density, frequent bone

fractures and pain. The pathology of osteoporosis is a decrease of bone formation as well
as an increase of bone resorption (uncoupling), which results in the loss of bone mass.
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Thus, an understanding of bone formation can shed light on both the cause and treatment
of osteoporosis. The bone formation process includes osteoblast proliferation and
differentiation. The study of bone cell proliferation is well established, but less is known
about the molecular basis of bone cell differentiation, such as the differentiation of
mesenchymal cells into osteoblasts. More specifically, we want to know how ALP
activity is regulated in bone cells during cell differentiation. Because 1,25D3 is a very
well known bone cell differentiation factor which stimulates ALP activity in osteoblasts,
and because of the exciting finding that TGFBi synergistically potentiates ALP activity, in
the presence of 1,25D3, which was reported to be about 70 fold over the control level
(see Chapter three), studying the molecular mechanism of this synergism can help us
understand the osteoblast differentiation processes and find the best therapy for
osteoporosis treatment. The results can be directly related to the increase of bone cell
differentiation and bone formation. Studies of the mechanism of the interaction between a
locally produced growth factor, TGFBi and circulating steroid hormone, 1,25D3 will also
provide us the understanding on the regulation of osteoblast differentiation.

H.

Goals of the present study

The key observation I have is that 1,25D3 activated ALP activity in the human
MG63 osteosarcoma cells whereas TGFPi by itself did not. Treatment of MG63 cells
with 1,25D3 increased ALP 2-4 fold, while pretreatment of the cells with TGFpi
significantly enhanced the 1,25D3 -stimulated ALP activity about 10-70 fold over the
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untreated control. This suggests that TGF(3i may work in conjunction with 1,25D3 to
mediate 1,25D3 effects. The mechanism of this synergistic effect on the ALP induction
may be related to TGF(3 modification of the 1,25D3 signaling pathway.
The goal for the present studies is to determine the mechanism by which TGF|3
enhances the effect of 1,25D3 on ALP activity. To attain this goal, it is necessary to
determine: (1) whether the PKC signal transduction pathways are involved in TGF(3i and
1,25D3 action on stimulation of ALP activity in MG63; (2) if the answer is YES, I want
to know how many PKC isozymes are expressed in human MG63 cells; (3) which PKC
isozyme(s) are involved in the TGFBi and 1,25D3 signal transduction pathway in MG63
cells; and (4) how does TGF(3i modify the action of 1,25D3 to further enchance the
1,25D3 ~ induced ALP activity? The approach for these studies was: (1) assay of ALP
activity and protein content, (2) Northern blot analysis to measure ALP mRNA and VDR
mRNA, (3) using Western blot, we can measure PKC isotype and VDR protein level,
and (4) radiolabeling and immunoprecipitation of VDR to measure the phosphorylation
level of VDR.

CHAPTER TWO
II.
A.

MATERIALS AND METHODS

Materials
1. Reagents
Dulbecco’s Modified Eagle’s Medium (DMEM) and phosphate-free DMEM were

purchased from Gibco Laboratories (Grand Island, NY). TGFpi was obtained from
Austral Biologicals (San Ramo, CA). The 1,25 dihydroxyvitamin D3 was a gift from Dr.
Millan R. Uskovic of Hoffman Laboratory Roche Inc. (Nutley, NJ).

Phorbol

myristate acetate (PMA), phosphatidylserine, histone Ha, bovine serum albumin (BSA),
p -nitrophenyl phosphate (PNPP) and Folin-Ciocalteu’s phenol reagent were purchased
from Sigma Chemical Company (St.Louis, MO). Staurosporine was purchased from
Calbiochem (San Diego, CA). Acrylamide, bis-acrylamide, ammonium persulfate and
TEMED were purchased from Bio-Rad laboratories (Richmond, CA). Anti-VDR
polyclonal antibody was obtained from Dr. Tuohimaa and made from rabbit by
immunoinjection with a synthetic hYDR peptide conjugated with BSA, as previously
described (Tuohimaa et al., 1992). Monoclonal mouse anti-PKC isoform IgG antibodies
were purchased from Transduction Laboratories. (Lexington, KY). The polyclonal
donkey anti-rabbit IgG antibody, goat anti-mouse IgG antibody and BCIP-NBT alkaline
phosphatase substrate kits were purchased from Pierce (Rockford, IL). Protein A
conjugated—argarose beads were purchased from GIBCO\BRL Life Technologies Inc.
(Gaithersburg, MD). Low melting point agarose was purchased from FMC BioProducts
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(Rockland, ME). All other reagents were obtained from Sigma Chemical Company (St.
Louis, MO), USB (Cleveland, OH), and Fisher Scientific (Tustin, CA).
Radiolabeled 32P-orthophosphate, a-[32P]-dCXP (3000 Ci/mmol) and y-[32P]-ATP
(7000 Ci/mmol) were purchased from ICN Biomedicals Inc. (Costa Mesa, CA). Vitamin
D receptor (VDR) (ATCC # 61260) and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (ATCC # 57090) cDNA probes were purchased from ATCC (Rockville, MD).
The human alkaline phosphatase oligonucleotide probe was synthesized by the Loma
Linda University Center for Molecular Biology and Gene Therapy (Loma Linda, CA).
The Klenow fragment of DNA polymerase I was purchased from Pharmacia (Piscataway,
NJ). T4 polynucleotide kinase, restriction enzymes and buffers were obtained from
Promega (Madison, WI) and GIBCO/BRL Life Technologies Inc.(Gaithersburg, MD).
2. Miscellaneous Materials
MagnaGraph nitrocellulose membranes and Nitropure nitrocellulose membranes
were purchased from Micro Separations Inc. (Westborough, MA). The p81 phosphate
paper was purchased from Whatman LabSales Inc. (Hillsboro, OR). Mermaid kits were
purchased from Biol01 Inc.(La Jolla, CA). Culture dishes and polypropylene tubes were
obtained from Corning Glass Works (Corning, NY). Multi-well plates were purchased
from Costar (Cambridge, MA).
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B.

Methods
1. Cell cultures
MG63 (American Type Tissue Culture Collection, Rockville, MD) cells were

cultured inDMEM with 10 % calf serum (CS) at 37°C and 5% C02.

1,25D3 stock

solution of 10 '4 M was prepared in 100 % ethanol and stored at -80 °C. 100 ng/ml of
TGFpi stock solution was made by dissolving TGFPi in 10 mM acetic acid solution and
also stored at - 80 °C. The final concentration of 1,25D3 (10 '8 M) was made by further
dilution of 1,25D3 stock solution with DMEM supplemented with 0.1 % BSA
immediately before adding to the cell cultures. Different doses of TGFpi were made by
directly diluting stock solution with DMEM containing 0.1% BSA.
For the ALP activity assays, cells were plated in the 24-multiwell plates at the
density of 50 cells/mm2. For Western blot, Northern blot, and protein kinase activity
assays, cells were cultured in 100 mm dishes at a density of 200 cells/mm2. When cells
were 70 to 80% confluent, the medium was replaced with serum-free DMEM
supplemented with 0.1% BSA for 24 hours. The medium was then removed and fresh,
serum-free DMEM supplemented with 0.1% BSA containing either TGFpi, 1,25D3 or
vehicle (0.01% ethanol at concentrations equivalent to that used in 1,25D3 solution) was
added. Cells were harvested and extracted with specific buffers for the different
biochemical assays.
2. Assay for ALP (EC 3.1.3.1) Activity
Briefly, cells were cultured in 24-well plates in serum-free medium. After 2 or 3
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days of treatment with effectors, the medium was drawn off and the cells were rinsed
twice with phosphate-buffered saline (PBS). Subsequently 0.2 mL of 0.1% Triton X-100
was added to each well and the plates were stored in - 20 °C freezer. The biochemical
determination of ALP activity was performed by a modification of Lowry et al. (1954) in
a reaction mixture containing 30 mM para-nitrophenyl phosphate, 150 mM sodium
carbonate buffer, and 1 mM MgCl2 at pH 10.3 with a final reaction volume of 0.2 ml in
a 96-well plate. The ALP activity in extracts was determined by measuring the rate of
hydrolysis of p-nitrophenyl phosphate to p-nitrophenol which has a yellow color with
maximum absorbence at 410 nm. The reaction was initiated by the addition of cell extract
(0.05 ml) and the mixture was incubated at room temperature for 2 hours. The
absorbance was determined with a Dynatech Microwell Plate Reader (Richmond, VA)
at 410 nm against a reference wavelength of 490 nm.
Protein concentrations of the cell extracts were determined using the Folin-phenol
method ( Lowry et al., 1951 ) with BSA as a standard. Briefly, a series of 100 (al of
diluted standard BSA solution (concentration from 5 fig to 100 jag) were used to
produce a standard curve and 100 (al of cell extract was added to each well of 96 well
plates. After adding the copper solution (Na2C03, CuS04 and NaK tartrate) and Folinphenol solution, the plates were incubated at room temperature for 20 minutes and then
submitted to centrifugation at 1500 rpm for 5 minutes to precipitate the Triton X-100.
100 (al of supernatant from each well was used to test absorbance at 690 nm with a
Dynatech Microwell Plate Reader (Richmond, VA).
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The final ALP activity was calculated as milliunits per milligram of protein and
reported as percentage of vehicle treated control. A milliunit of ALP activity was defined
as the amount of enzyme needed to catalyze the production of 1 nanomole pnitrophenol from p-nitrophenyl phosphate per minute at room temperature (21°C).
3. RNA manipulation
(1) Isolation and labeling of VDR and GAPDH cDNA probes
A 600 bp fragment of the human VDR cDNA probe was cut from vector plasmid
pGEM-3 by Pst I restriction endonuclease and purified by gel electrophoresis. The
GAPDH cDNA probe was a 780 bp gel - purified Pxt I/Xbal fragment containing the
5’-noncoding and coding regions (Fort et al., 1985). Briefly, the plasmid DNAs were
digested with appropriate restriction endonucleases for 12 to 24 hours. The cDNA insert
was separated from the vector on a low melting 1% agarose gel using IX TBE as the
running buffer. After visualization with ethidium bromide, the desired cDNA insert
fragment was cut out of the gel, melted at 70 °C and combined with an equal volume of
DEPC water (Chapter four). The cDNA probe was aliquoted prior to storage at -20 °C.
Before labeling, the agarose with cDNA probe was melted at 70 °C for 5 minutes.
The cDNA probes were labeled by the random priming method (Feinburg et al.,
1983). A 50 to 100 ng aliquot of cDNA insert was diluted in water to 31 pi and boiled for
5 minutes. The denatured cDNA was then cooled on ice for several seconds. 10 pi of
cDNA labeling mix (dNTP), 2 pi of DNAse-free BSA (10 mg/ml), 5 pi of
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a-[32P]-dCTP (50-100 jaCi) and 2 jal of Klenow fragment of DNA polymerase I
(1 unit/|iil) were added to the denatured cDNA solution in order. The mixture was gently
agitated and incubated at 37 °C overnight.
The labeled probe was separated from free a-[32P]-dCTP by chromatography of
NACS. Briefly, the NACS column was hydrated with 3 mL Tris-EDTA (TE)/2 M NaCl
buffer and subsequently equilibrated with 5 ml of TE/0.2 M NaCl. The cDNA probe
mixture was loaded into the column twice and the bound cDNA probe was washed with 5
ml of TE/0.2 M NaCl. The labeled probe was eluted from the column with 500 pi of TE/2
M NaCl and the amount of 32P incorporation (labeling efficiency) was measured by liquid
scintillation counting.
(2) ALP Oligo probe labeling
The L/B/K ALP oligo probe, a synthesized 40 mer oligodeoxynucleotide, was
labeled by the method of Ausubel et al.(1994). Briefly, the 10 pi reaction mixture
containing 50-100 ng of probe, 1 pi of 10 X TMDSE buffer (Chapter Four), 200 pCi
y-[32P]-ATP and 1 unit of T4 polynucleotide Kinase. The mixture was incubated at 37
°C for 45 minutes and the labeled oligo was purified with a Mermaid™ kit. For 10 pi of
labeling reaction, 30 pi of High Salt Binding Solution and 5 pi of Glassfog beads were
added, vortexed vigorously and incubated at room temperature for 15 minutes. The
supernatant was removed following pulse centrifugation and the pellet was washed twice
with 300 pi of ethanol washing solution. The pellet was air-dried for 5 minutes and the

34

labeled probe was eluted twice from the Glassfog beads with 100 pi of 60 °C DEPC
water. The amount of 32P incorporated was determined by liquid scintillation counting.
(3) RNA separation and Northern blot
Total cellular RNA was extracted using the single step of acid guanidiniumthiocyanate phenol-chloroform method as described by Chomczynski et al. (1987).
Briefly, the cell culture dish was washed once by cold PBS and extracted with 1 ml of
solution D (Guanidinium buffer). The cell extract from several dishes was collected,
combined and stored at -80 °C. For RNA purification from total cell extract, 0.1 volume
of 2M sodium acetate (pH 4.0), 1 volume of DEPC water-saturated phenol and
0.2 volume of DEPC water saturated-chloroform/IAA (49:1) were added to the cell
extracts sequentially with complete mixing. The extraction mix was vortexed vigorously
and incubated on ice for 20 minutes and then centrifuged at 10,000 x g for 30 minutes at 4
°C. The upper aqueous layer containing the total RNA was transferred to a new 50 ml
tube and the RNA was precipitated by adding one volume of cold isopropanol and stored
at -20 °C overnight or on dry ice for 2 - 4 hours before further use. The RNA was
precipitated by centrifugation at 10,000 x g for 30 minutes and 4 °C. The RNA pellet
was redissolved in 500 pi of solution D and precipitated again by adding an equal volume
of isopropanol and stored at - 20 °C overnight.
The final RNA purification step was done by centrifugation of RNA at 14,000 x g
for 10 minutes and washing the RNA pellet with - 20 °C 80 % ethanol twice. The RNA
pellet was dissolved in 40 pi of DEPC water and the concentration was measured by

35

reading the OD value at 260 run and 280 nm respectively. The purity of RNA was
estimated by calculating the 260/280 ratio and only the samples which had a ratio greater
than 1.7 were used for Northern blot analysis.
Equivalent amounts of RNA (20 pg for VDR and 40 pg for Alkaline phosphatase
Northern blots respectively) were denatured at 65 °C and applied to a 1.5% agarose gel
containing 2.2 mM formaldehyde and 1 X MOPS buffer (Chapter four). The RNA was
transferred from the gel to Magnagraph Nitrocellulose paper overnight with 10X SSPE
(Maniatis et al., 1982). Blots were crosslinked by UV cross-linker, air dried, then baked
at 80 °C for 1 hour. The membrane was stained with methylene blue to label the 18S and
28S rRNA bands as size markers and evaluate RNA loading, transfering efficiency and
degradation (Herrin et al., 1988).
(4) RNA hybridization and autoradiography
Northern blot filters were prehybridized in 50% formamide, 5X SSPE, 5X
Denhart’s, 200 pg/ml denatured sperm DNA and 0.1% sodium dodecyl sulfate (SDS) for
2 hours at 42 °C. Hybridization was performed overnight at 42 °C in prehybridization
buffer plus 10% dextran sulfate and either 106 dpm/ml 32P labeled VDR cDNA probe or
105 dpm/ml 32P labeled GAPDH cDNA probe. After hybridization, the filters were
washed sequentially with 6 X SSPE, 2 X SSPE and 1 X SSPE for 30 minutes each at
42 °C.
For L/K/B ALP mRNA hybridization, the filters were prehybridized in 6X SSPE, 5
X Denhart’s, 200 fig/ml transfer RNA and 0.1% SDS for 2 hours at 45 °C. Hybridization
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was carried out overnight at 45 °C in 6 X SSPE, 1 X Denhart’s, 0.1% SDS, 10% dextran
sulfate, 200 (ag/ml denatured transfer RNA and 106 dpm/ml of radiolabeled ALP
oligodeoxynucleotide probe. Filters were washed twice with 6X SSPE / 0.1% SDS, once
with 2X SSPE/0.1% SDS.
The blots were autoradiographed at - 80 °C for 3 -10 days with Fuji x-ray film
using DuPont Cronex III intensifying screens. After autoradiography, the relative density
of the mRNA bands were measured with a laser-scanning densitometer (Biomed.
Instruments, Fullerton, CA) and normalized to the densities of methylene blue stained 28S
ribosomal RNA bands from same experiment.
4. Protein kinase activity assay
(1) Cell fractionation
Prior to extraction, cells were washed twice with cold phosphate-buffered saline
(PBS) and extracted immediately with Buffer A (Chapter four). The cell suspension was
sonicated (total cell extract) followed by centrifugation at 500 x g for 5 minutes to
remove the nuclear components and undissolved debris. The supernatant underwent
further ultracentrifugation at 100,000 x g for 20 minutes. The cytosolic fraction
(supernatant) and membrane (pellets) were collected and re-dissolved in Buffer B (Buffer
A containing 0.3% Triton X-100). At this point, both the membrane and the cytosol
fractions were assayed for protein content by the Bradford method (Bradford, 1976).
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(2) Protein kinase C activity assay
The PKC protein in the cytosol and membrane fractions were further enriched by
absorption with 250 pi of DEAE-sephadex beads and then eluted with elution buffer
(150 mM NaCl in Buffer A). PKC activities in the cytosol and membrane were
determined by measuring 32P incorporation from [y- 32P] ATP into histone Ha under
conditions where histone phosphorylation was proportional to enzyme concentration (Wali
et al., 1990). The reactions were carried out in 150 pi reaction buffer (Appendix). The
lipid suspension (phosphatidylserine) was prepared by suspending in Buffer B (Appendix)
and dispersing by sonication. The reaction was started by adding the cytosol and
membrane protein to the reaction buffer and incubated for 8 minutes at 30 0 C. The
reaction was terminated by transferring the reaction mixture to p81 phosphate paper which
was then soaked in 10 % trichloroacetic acid buffer. After tap water rinsing and final
acetone wash, the papers were dried, and radioactivity was determined by scintillation
counting. Protein kinase C activity is reported as the difference in 32P incorporation into
histone II in the presence or absence of phosphatidylserine and diolein. All values
represent the mean from six replicates.
5. Western Blot
(1) VDR protein expression
To assay VDR protein level, the cells from at least four 100 mm culture dishes
were combined for each treatment. Briefly, the cell layer was washed twice with ice cold
PBS and extracted with 0.5 ml of native extraction buffer (Appendix). The cell extracts
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were sonicated at power 5 for 30 seconds and immediately further diluted with Laemmlli
buffer. At this step, the samples can be stored at - 80 °C for further usage.
Because the VDR protein is nucleophilic (Tuohimaa et al., 1992), nuclei from cell
extracts were precipitated by 500 x g centrifugation at 4 °C for 10 minutes. The pellet
(nuclei) was dissolved in denaturing gel buffer (Appendix), further diluted with Laemmlli
buffer and boiled for 5 minutes. The nuclear extract was submitted to centrifugation at
13,000 x g for 30 minutes at 4 °C and an aliquot of the supernatant was used for protein
content assay by the Bradford dye binding method (Bradford, 1976).
The supernatant from the nuclear fraction dissolved in denaturing gel buffer was
mixed with Laemmli gel sample buffer (Laemmli et al., 1970) at 1 to 2 ratio by volume
and boiled for another 5 minutes before loading on a 7.5 % SDS-PAGE gel. After gel
electrophoresis, proteins were electroblotted from the gel onto Nitropure nitrocellulose
membrane for 1 hour at 100 V (constant voltage) in transfering buffer as described by
Towbin et al. (1979). Prestained molecular weight markers (Bio-Red) were
electrophoresed in parallel. The nitrocellulose membrane was incubated with primary
polyclonal rabbit anti-human VDR antibodies following the protocol described by
Tuohimaa et al. (1992). Briefly, non-specific binding of the membrane was blocked for
30 minutes in TBS-T blocking buffer containing 5% dry milk. The membrane was further
incubated with 2 pg/ml of primary anti-VDR antibodies at 4 °C overnight. The alkaline
phosphatase-conjugated secondary donkey anti-rabbit IgG antibodies were diluted at
1:6000 in TBS-T blocking buffer containing 1% dry milk. The membrane was incubated
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with above secondary antibodies for one hour.

Color was developed from the ALP

conjugated secondary antibodies using the alkaline phosphatase substrate BCIP and NBT
(Pierce). Between each step of the immunodetection, the membranes were washed five
times at 5 minutes each in blocking buffer. The specificity of the secondary antibodies
was determined by incubation of a parallel membrane without primary antibodies.
(2) PKC isoform expression in MG63 cells
Western blot analysis was carried out according to Bomer et al.(1987). MG63
cells were washed twice with cold PBS, extracted immediately with native extraction
buffer (Appendix) and kept at 4 °C. The cell suspension was sonicated (total cell extract)
followed by centrifugation at 500 x g for 5 minutes to remove the nuclear components
and undissolved debris. The supernatant underwent ultracentrifugation at 100,000 x g for
20 minutes to separate the cytosolic fraction (supernatant) and the membrane fraction
(pellets). At this point, aliquots from each sample were assayed for protein content by
the Bradford method.
Aliquots of the membrane and cytosol samples were mixed with Laemmili gel
sample buffer and boiled for 5 minutes prior to loading on the 12 % SDS-PAGE. The
electrophoresis and protein transferring procedure were carried out as described in the
section of Western blot VDR protein expression. Incubation of the membrane with PKC
antibodies was performed essentially as previously described (Borner et al., 1987).
Briefly, non-specific sites were blocked in TBS-T containing 2% BSA for 30 minutes at
room temperature. Membranes were then incubated with the PKC antibodies (1 ug/ml) in
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the blocking buffer overnight at 4 °C. After rinsing away the unbound primary antibody,
the nitrocellulose membranes were further incubated with the secondary alkaline
phosphatase-conjugated goat anti-mouse IgG antibodies for 60 minutes. The secondary
antibody was diluted to a final dilution of 1:4000 in blocking buffer. Following the last
wash, alkaline phosphatase substrate (BCIP and NBT) was used for color development.
6. VDR phosphorylation and immunoprecipitation
A modification of a previously reported procedure (Harlow et al., 1988) was used
for this assay. Briefly, MG63 cells were seeded in 100 mm dishes. After reaching 80%
confluence, the cell layer was washed twice with phosphate-free DMEM followed by
incubation in 3 ml/dish of phosphate-free DMEM supplemented with 1% dialyzed calf
serum and 0.5 mCi of [32P]-orthophosphate for two hours to prelabel the cells. Effectors
were added for an additional two hour incubation at 37 °C and the cells were then washed
twice in 5 ml of cold immunoprecipitation PBS washing buffer (Appendix). The cells
were extracted by adding 0.5 ml of denaturing extracting buffer (Appendix) and boiled for
5 minutes. After sonication of the cell extract, the lysates from 32P labeled cells were
centrifuged at 13,000 x g for 30 minutes to remove the insoluble cell protein.
The supernatant from the above centrifugation was used for the
immunoprecipitation assay. Briefly, in a microcentrifuge tube, five fig of anti-VDR
polyclonal antibody ahVDR-103 (Tuohimaa et al., 1992) and 500 jag of total cell protein
were mixed with 500 pi of 2X immunoprecipitation buffer (Appendix). Additional water
was added to bring the total volume to 1 ml. The tubes were shaken at 4 °C overnight.
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The protein A agarose beads were prepared by washing with IX immunoprecipitation
buffer three times. Finally, the protein A agarose beads were resuspended in the initial
volume to give a 10% suspension and stored at 4 °C.

Fifty pi of 10 % protein A-agarose

beads were added to each immunoprecipitation sample and continuously shaken for
another 30 minutes.

The samples were then extensively washed with ice-cold 1 X

immunoprecipitation buffer. Finally the immunoprecipitation complex was eluted out
with 30 pi of Laemmli buffer and boiled for 5 minutes.

The 12% SDS-PAGE gels were

run at 200 V (constant voltage) and stained with coomassie brilliant blue R-250.
Autoradiography of the gels was performed by drying and exposing to X-ray film at
- 70 °C. The final radioactive VDR bands were scanned with a laser-scanning densitometer
(Biomed Instruments, Fullerton, CA).
7. Statistical methods
The statistical significance of the treatments was first tested by two or three way
ANOVA. If ANOVA indicated statistically significant effects, the results were further
analyzed by the two tailed student’s test. The results in this paper are presented as the
mean ± SD of two to six replicates. Statistical significance means p< 0.05 (*) or p<0.01
(**).

CHAPTER THREE
III.

INVOLVEMENT OF PROTEIN KINASE C IN STIMULATION

OF ALKALINE PHOSPHATASE ACTIVITY BY TGFfil AND 1, 25DIHYDROXYVITAMIN D3 IN HUMAN MG63 OSTEOSARCOMA
CELLS

A.

Introduction
Transforming growth factor Pi (TGFBi) and the circulating steroid hormone,

1,25D3 or calcitriol, are very well known cell differentiation agents. 1,25D3 has been
reported to play an important role in regulating osteoblast differentiation (Evans et al.,
1989; Halline et al., 1994), such as the increase of the osteocalcin and collagen synthesis
and activation of ALP activity (Skjodt et al., 1985; Franceschi et al., 1988; Kemer et al.,
1989). TGFBi is a locally produced growth factor and is abundant in bone (Hauschka et
al., 1986; Robey et al., 1987). As a potential differentiation factor for osteoblastic cells,
TGFBi has been reported to interact with 1,25D3 and modulate its biologic response (Yen
et al., 1993; Chang et al., 1993), notably the observation that TGFBi and 1,25D3
synergistically stimulated ALP activity in human osteoblast and MG63 osteosarcoma cells
(Wergedal et al., 1992; Bonewald et al., 1992). The mechanism for this interaction is still
unknown.
Because signal transduction pathways play an important role in regulating different
cellular events, I postulate that a TGFBi-initiated signalling pathway may interact with
1,25D3 to enhance the ALP activity. TGFBi has been reported to affect multiple
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signalling pathways including the activation of serine/threonine protein kinases (Ohtsuki et
al1992; Howe et al., 1991; Shibanuma et al., 1992); the stimulation of protein
phosphatases (Gruppuso et al., 1991); the activation of guanine nucleotide binding
protein (Murthy et al., 1988; Mulder et al., 1992); protein kinase A (Anderson et al.,
1993), protein kinase C (Sylvia et al., 1994), and also the increase of the
phosphorylation of several nuclear proteins (Lue et al., 1993; Kramer et al., 1991). Both
TGFBi and 1,25D3 have an effect on PKC activation in a series of cell lines (Wrenn et al.,
1993; Bissonnette et al., 1995; Wali et al., 1990) but the effects on bone cells have not
been reported. PKC, as a Ca++ activated, phospholipid dependent protein kinase, is
known to play key roles in a variety of cellular processes (Nishizuka,1995). The functional
involvement of this ubiquitous enzyme in signaling pathways to regulate cellular response
has been demonstrated by the use of the PKC activators and inhibitors of these processes
(Kikkawa et al., 1986; Hannunetal., 1986). One of the most widely used activators is
Phorbol myristate acetate (PMA), which can directly bind and activate most PKC
isoforms. Staurosporine, a microbial alkaloid, is a potent inhibitor of PKC at nM
concentrations. It blocks the enzyme by interacting with the catalytic domain, but does
not prevent phospholipids and Phorbol esters from binding to protein kinase C.
In the present studies, my goal is to examine whether there is an involvement of
the functional PKC pathway in the action of TGFBi and 1,25D3 on ALP activity. Using
staurosporine and PMA to block or activate the PKC pathway (Figure 9), we have
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provided evidence that PKC is functionally involved in the TGFBi and 1,25D3 effects on
ALP activity in human MG63 cells.

B.

Results
Because the PKC pathway may be involved in TGFBi and 1,25D3 stimulated ALP

induction, we tested the hypothesis that the changes in ALP activity and ALP mRNA
levels were mediated by PKC. Using a PKC pathway blocker and PKC activator, the
data showed that the PKC pathway is functionally involved in both TGFBi and 1,25D3
induction of ALP.
1. Evidence that staurosporine blocks induction of ALP activity by 1,25D3
and 1,25D3 plus TGFBi
(1) Effect of staurosporine on TGFBi and l,25D3-stimulated ALP activities.
MG63 cells were treated with 1 ng/ml TGFBi, 10 8 M 1,25D3 and the combination of the
TGFBi plus 1,25D3 in serum-free medium for 48 hours in the presence or absence of
0.5 nM staurosporine (Table 1). TGFBi alone had little effect on ALP stimulation. 1,25D3
significantly increased ALP activity about 1.6 fold which was statistically significant.
Addition of 0.5 nM staurosporine did not change the basal level of ALP activity and did
not alter the effect of TGFBi. Co-incubation of staurosporine with 1,25D3 or with the
combination of TGFBi plus 1,25D3 resulted in 50% inhibition of 1,25D3 - induced ALP
activity and 92 % inhibition of the combination -induced ALP activity.
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The effect of staurosporine on l,25D3-stimulated ALP activity in the presence of
different doses of TGFBi was further tested. As shown in Figure 10, staurosporine at
0.5 nM inhibited 100 % and 90 % of ALP activity induced by 0.1 ng/ml and 0.5 ng/ml of
TGFBi in the presence of 1,25D3. Staurosporine blocked only 68% of the ALP activity
stimulated by 1 ng/ml TGFBi plus 1,25D3. It is possible that there is a competition
mechanism between the staurosporine and TGFBi effects.
(2) Dose dependent inhibition of staurosporine on ALP activity induced by TGFBi
and 1,25D3. MG63 cells were treated with 1 ng/mL TGFBi, 10 '8 M 1,25D3; and different
concentrations of staurosporine (Figure 11). Staurosporine at a doses of 0.05 nM and
0.5 nM significantly blocked the increase of ALP activity induced by the combination of
TGFBi and 1,25D3. The inhibition rate was about 25 % by 0.05 nM staurosporine and
95% by 0.5 nM staurosporine respectively (p< 0.01). Staurosporine at 0.01 nM had little
effect on the induction of ALP activity by the combination of TGFBi and 1,25D3.
Therefore, the staurosporine inhibitory effect on ALP is in a dose-dependent manner. The
concentration of staurosporine from 0.01 to 0.5 nM in serum-free medium is not toxic for
the cells.
(3) Effect of Staurosporine on ALP mRNA level increased by TGFBi and 1,25D3.
The goal of performing the Northern blot was to test whether staurosporine blocking
TGFBi and l,25D3-induced ALP activity is due to a decrease of the ALP mRNA levels.
Our results showed that MG63 cells express a very low basal level of ALP mRNA and
that staurosporine had no effect on this basal level of ALP mRNA expression (Figure
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12A). Both TGFBi and 1.25D3 alone appeared to slightly increase ALP mRNA levels but
the results were not statistically significant. A marked ALP mRNA increase about 800%
increase over the control can be seen in the TGFBi plus 1,25D3 group (Figure 12A), which
is statistically significant (Figure 12B). 0.5 nM staurosporine significantly blocked the
combination-stimulated ALP mRNA level by 80%.

2. Evidence that PMA potentiates ALP activity stimulated by 1,25D3 and
TGFBi plus 1,25D3
If a PKC pathway is involved in TGFBi action to enhance 1,25D3 stimulated ALP
activity, the PKC activator, PMA, should mimic the TGFBi effect. Like TGFBi, 10'7 M
PMA had little effect on the basal cellular level of ALP activity but synergistically
increased l,25D3-stimulated ALP to 520% of control level (Table 2). In contrast with
either TGFBi or PMA alone, the combination of TGFBi and PMA showed a synergistic
effect on the induction of ALP activity which was about 300% of the control level. This
combination further enhanced l,25D3-stimulated ALP activity to 1440% over the control
level. It was 220% higher than ALP activity induced by the combination of TGFBi plus
1,25D3 or 280% higher than that induced by PMA plus 1,25D3.
The dose effect of TGFBi or PMA in the presence of 1,25D3 was further tested
(Figure 13). There was a dose-dependent increase of ALP activity when MG63 cells
were incubated with 0.1 to 1 ng/mL TGFBi or 10 '9 M to 10 ’7 M PMA in the presence of
10 '8 M 1,25D3. Although the induction of ALP activity by both TGFBI plus 1,25D3 and
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PMA plus 1,25D3 was in a dose-dependent manner, the ALP activity induced by TGFB1
plus 1,25D3 was higher than the combination of PMA plus 1,25D3.

C.

Discussion
In the past few years, studies of several cell types have shown that 1,25D3

modulates various intracellular messenger systems, i.e. calcium, PKC and PKA
(Lieberherr et al., 1987; Martell et al.,1987; Obeid et al.,1990; Barsony et al., 1988;
Wali et al., 1990; Lissoos et al., 1993). Because the above signal transduction pathways
are initiated rapidly, it has become accepted that 1,25D3 has cell membrane effects and
affects several signaling related kinases, including PKC by a mechanism which is assumed
to be related to the 1,25D3 membrane receptor. PKC involvement has been documented
in 1,25D3 pathways, i.e., PKC inhibitors reduced 1,25D3 -stimulated cell differentiation in
HL-60 leukemia cells and osteoblastic cells (Simpson et al., 1989; Van-leeuwen et al.,
1992); PKC was involved in the stimulation of de novo synthesis of osteocalcin by 1,25D3
in the ROS17/2.8 cell line and ROB cells (Jones et al., 1991). The current study provides
evidence that PKC is involved in the induction of ALP by 1,25D3.
TGFBi has been detected in a wide range of tissues and nearly all cells. It is
postulated that TGFBi may be involved in a broad spectrum of physiological functions and
many mechanisms may exist for TGFBi effects (Kim et al., 1989). It has been suggested
that TGFBi as a multifunctional cytokine can modify the biological effect of other factors
(Sporn et al., 1986).

The synergistic effect of TGFBi and 1,25D3 on ALP activity in
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normal and osteosarcoma cells has been confirmed in the present study. It is essential to
obtain insight into the functional role of signal transduction pathways, especially PKC
which could have an important role on the biological response to TGFBi and 1,25D3. The
present study was designed to investigate the functional involvement of PKC in the action
of TGFBi, 1,25D3, and the combination of TGFBi plus 1,25D3 in human bone MG63 cells.
This is the first evidence that PKC is functionally involved in the 1,25D3 action on
the ALP activity in MG63 cells and normal human bone cells (data not shown), because
staurosporine and PMA significantly either blocked or potentiated l,25D3-stimulated
ALP activity. Interestingly, PMA, as a specific PKC pathway activator, can further
enchance the induction of ALP by 1,25D3. The interpretations for these results are: (1)
1,25D3 increased ALP activity through its steroid genomic effect mediated by its nuclear
receptor-nVDR (Kyeyune-Nyombi et al., 1991). However, staurosporine, which is a
PKC specific inhibitor, blocked the l,25D3-induced ALP activity, which means that
1,25D3 has a PKC-mediated pathway which is also involved in ALP induction. We
assume that this membrane effect of 1,25D3 may play a role through PKC in modulating
its genomic effect. (2) because the PKC activator, PMA, can further enhance 1,25D3 ’s
function to stimulate ALP activity, it is suggested that the 1,25D3 mediated-PKC pathway
was not fully activated, but can be further increased by PMA. This further supports the
hypothesis that the PKC activation is important for 1,25D3 mediated ALP induction and
stimulation of osteoblast differentiation. (3) the interaction between PKC and 1,25D3 also
suggests the possibility that the PKC phosphorylates and activates the VDR because PKC
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has been reported to selectively phosphorylate the human vitamin D receptor (VDR) on
serine 51 (Hsieh et al., 1991; Hilliard et al., 1994). Phosphorylated VDR functions as a
transcriptional factor to positively affect gene transactivation (Darwish et al., 1993).
In the present study, we have also shown a possible role for PKC in the TGFB
action onMG63 cells. Even though our data did not show a staurosporine inhibitory
effect on TGFBi action (TGFBi alone was not an ALP stimulator in our experiments), the
PKC activator, PMA, exactly mimicked TGFBi action on ALP activity: i.e. PMA alone did
not affect the basal level of the ALP activity but it potentiated the 1,25D3 effect on ALP in
a time-dependent manner. Surprisingly, we found that both TGFBi and PMA individually
had no effects on ALP induction but the combination of these two factors showed a
synergistic effect. We postulate that TGFBi has multiple signalling pathways and one of
them may be directly related to the ALP induction which was observed in normal human
bone cells in our laboratory (data not shown) and also oberserved in MG63 cells
(Bonewald et al., 1992). TGFBi as a multifunctional cytokine was reported to have
varying effects on the cell functions depending on experimental conditions: i.e the cell
density, serum presence, and cell stage (Wergedal et al., 1992; Robey et al., 1987; Noda
et al., 1987; Elford et al., 1987; Noda et al., 1986).

Dr. Bonewald et al. (1992)

demonstrated that TGFBi at higher dosage such as 5 to 10 ng/ml stimulated ALP activity
in human MG63 cells. This result may suggest that at physiological doses, TGFBi exerts
less effect on ALP induction but we cannot rule out the existance of this effect. The
higher dose of TGFBi may enhance this effect or activate another pathway and result in
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stimulation of the ALP activity. Our data provide further evidence that at least PKC
activation can potentiate the TGFBi effect on ALP activity.
In summary, the current studies demonstrate that PKC is involved in TGFBi and
1,25D3 action and further that the activation of the PKC pathway synergistically increase
the l,25D3-stimulated cellular level of alkaline phosphatase activity.

Therefore, it is very

important to further study TGFBi and 1,25D3 effects on PKC isozyme expression and
regulation as well as VDR phosphorylation and induction in MG63 cells. Finally, the
current studies provide a clue to the interaction mechanism of a locally produced growth
factor, TGFBi, and a circulating hormone, 1,25D3, and how they co-operate to regulate
osteoblast differentiation.
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IV.

EXPRESSION OF SEVEN PKC ISOFORMS IN HUMAN

MG63 OSTEOSARCOMA CELLS — THEIR SUBCELLULAR
DISTRIBUTION AND REGULATION BY PMA

A.

Introduction
Osteoblasts are cells involved in bone formation as well as bone resorption. Many

hormones and growth factors regulate these processes (Skjodt et al., 1992). The action
of growth factors on cells is mediated by their membrane receptors which play a role in
transducing the signal across the membrane to activate signal transduction pathways. Our
previous data provided evidence that protein kinase C (PKC) pathways were functionally
involved in the stimulation of ALP by either TGFPi or 1,25D3 as well as the combination
of TGFpi and 1,25D3 ( Chapter three). To further study the possible role of PKCmediated pathways on ALP induction by TGFpi and 1,25D3, we explored PKC isoform
expression, distribution and response to the PKC activator (PMA) in MG63 cells.
The PKC family has at least ten isoforms (Nakamura et al., 1994) with closely
related structures, most of which are activated by phospholipid and DAG (or PMA),
albeit with slightly different kinetics (Nishizuka et al., 1992; Kikkawa et al., 1989). One
difference between isoforms is their sensitivity to Ca^. The conventional PKCs (cPKCa,
BI, BII, and y) are Ca^-dependent for activation (Burns et al., 1990; Hannun et al.,
1990), whereas, the novel PKCs (nPKC5, s, and 0) are not dependent on Ca++ (Ono et
al., 1989a; Schaap et al., 1990a). The third class of PKC is aPKC (k and i) which is
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also Ca++-independent. Some members of this class do not respond to diacylglycerol
(DAG), or Phorbol esters (Selbie et al., 1993). It is suggested that each isoform may
exert a distinct cellular function based on the fact that different tissues have different PKC
isoform distribution and more than one isoform can be expressed in a single cell type
(Borner et al., 1992a; Nishizuka et al., 1988).
Among the signal transduction pathways, PKC is one of the major mediators of
signals generated by external stimulation of cells by hormones and growth factors (Borner
et al., 1992; Nishizuka et al., 1988). The signals for PKC translocation/activation include
the activation of phospholipases and the hydrolysis of phospholipids which generate DAG.
DAG is an endogenous activator of PKC causing PKC activation and translocation from
one compartment to others (i.e: from the cytosol to the membrane). This event is
reversible and transient in most cases due to the rapid metabolism of DAG (Nelsestuen et
al., 1991; Kikkawa et al., 1989). Phorbol esters such as phorbol myristate acetate
(PMA) can substitute for DAG in the activation of PKC (Castagna et al., 1992; Weinstein
et al., 1988). Due to its potency and in vivo stability ( because it is not hydrolyzable),
PMA is able to irreversibly activate and translocate PKCs to the lipid bilayer membrane,
and thereby cause accumulation and long-term stimulation of PKC (Nelsestuen et al.,
1991; Anderson et al., 1985). Another characteristic of the PMA effect on PKC is the
sensitivity of the PKC isoforms to long-term PMA induced down-regulation. The
mechanism of the down-regulation is that the membrane bound PKC is more sensitive to
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proteolytic degradation. The significance of this is unknown, but it may be one of the
regulation mechanisms to balance PKC activation.
In the present study, we employed eight PKC isoform antibodies and all of
antibodies were tested for specificity to their antigens by the provider (Transduction Lab.,
Lexington, KY). Our results showed that the MG63 cells expressed seven PKC isoforms;
all having different abundance, subcellular localization, and response to phorbol ester.

B.

Results
In the present studies, MG63 cells were treated with either vehicle or PMA for 30

minutes or 24 hours. Cells were then extracted and fractionated into the cytosol and
membrane as described in Material and methods. Western blot analysis was performed
with the monoclonal PKC isoform antibodies. The results provided evidence that MG63
expressed seven PKC isoforms but that PKCp was not detectable. Each isoform of PKC
showed different cellular localization and response to PMA treatment.
1. cPKC expression and regulation by PMA
(1). PKCa: PKCa is an 82 kDa molecular weight protein and is pre-dominantly
localized in the cytosol (Figure 14). Treatment of cells with 10 '7 M PMA for 30 minutes
resulted in a complete translocation of PKCa from the cytosol fraction to the membrane
(upper panel). A 24-hour treatment with PMA resulted in a depletion of the PKCa from
both cytosol and membrane fractions (lower panel).
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(2). PKCy: PKCy is a single 80 kDa protein and is distributed predominantly in
the cytosolic fraction (Figure 15). A 30 minute treatment with 10 '7 M PMA showed a
decreased PKCy band in the cytosol accompanied by the appearance of an intense band in
the membrane (upper panel). So PMA caused PKCy translocation from the cytosol to the
membrane. Like PKCa, PKCy was depleted or down-regulated by a 24-h PMA
treatment (lower panel) from both the cytosol and the membrane fractions.

2. nPKC expression and regulation by PMA
(1). PKC8: PKC5 is a 76 kDa protein which is pre-dominantly located in the
cytosol (Figure 16). Treatment of cells with 10 '7 M PMA for 30 minutes had no effect on
PKC5 membrane translocation (upper panel). A 24 hour treatment with PMA increased
PKC5 protein expression in the membrane (lower panel) without changing the cytosolic
protein level.
(2). PKCs: PKCs is a 90 kDa protein with a major band in the membrane and
minor band in the cytosol (Figure 17). A 30 minute treatment with 10 '7 M PMA reduced
the cytosol PKCs band and correspondingly increased the intensity of the membrane band
(the upper panel). A 24 hour treatment of cells with PMA decreased the membrane PKCs
band (the lower panel) with totally depleted PKCs band in the cytosol. Thus membrane
PKCs showed more resistance to long term PMA down-regulation.
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(3). PKC0: PKC0 is a 79 kDa protein. Like PKCe, it is mainly membrane located
(Figure 18). PMA at 10 '7 M had no apparent effect on the distribution of this PKC
isoform at either 30 minutes or 24 hours under our experimental conditions.

3. aPKC expression and regulation by PMA
(1). PKCA-: PKO, is a 74 kDa protein and is expressed in both cytosol and
membrane fractions with a stronger band showing in the cytosol (Figure 19). PMA at
10 '7 M had little effect on this enzyme at either 30 minute or 24 hour treatments.
(2). PKCi: PKCi is a 74 kDa protein and is expressed mainly in the cytosol
(Figure 20). PMA had no effect on PKCi translocation at either 30 minute or 24 hour
treatments.

4. Effect of PMA on total PKC activity and re-distribution
In untreated cells, total PKC activity was much higher in the cytosol and was
undetectable in the cell membrane. PMA at 10

M induced a strong, rapid total PKC

activity change between the cytosol and the membrane as determined by increased PKC
activity in the membrane (Figure 21 A), accompanied by decreased PKC activity in the
cytosol (Figure 2IB).

The membrane PKC translocation occurred as early as 5 second

with a peak at 30 minutes. After 30 minutes, PMA started down-regulating the
membrane-bound PKC. With longer exposure of cells to PMA, the cytosolic PKC
activity further declined but was no longer compensated by an increased PKC activity in
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membrane. Both the membranous and cytosolic PKC activity were depleted at 6 hours
and remained low for at least 24 hours with PMA treatment.

C.

Discussion
We tested for eight different PKC isoforms in the current studies and have

demonstrated for the first time that osteoblastic-like human MG63 osteosarcoma cells
express seven isoforms of protein kinase C detectable by Western blot analysis. PKCp
was undetectable in MG63 cells. The seven PKC isoforms were: cPKC (a and y), nPKC
(e, 0 and 8) and aPKC (X and i). To further investigate these PKC isoforms, we tested
the effect of PMA on their activation or translocation for a short term (30 minutes)
treatment and on their down-regulation for a long term (24 hours) treatment. In addition,
PMA-induced total PKC activity was measured to analyze the functional relationship
between PKC isoform protein levels and their total activity.
It has been suggested that PKC plays an important role not only in cellular
proliferation but also in cell differentiation. PKC is generally accepted to play a crucial
role in cellular signal transduction pathways (Duyster et al., 1993). The PKC family is
characterized by heterogeneity in localization, i.e. a PKC isoform localization can be
cytosolic (Kiley et al., 1990) or membranous (Strulovici et al., 1991; Dekker et al.,
1994) depending on the cell type. PKC isoforms also have specific activator requirements,
different redistribution responses to exogenous effector stimulation and involvement in
various cellular functions (Crabos et al., 1991; Huwiler et al., 1991). It is generally
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accepted that: (a) PKC activation means that PKC isoforms translocate from the cytosol
to the membrane in response to an activator, (b) PMA is a PKC activator but it has dual
action on the regulation of PKCs. Short term; seconds to minutes exposure of cells to
PMA causes PKC activation and long term, hour exposure causes either down-regulation
or depletion of PKCs.
PKCa and y are conventional Ca++ -dependent PKC. Both PKCa and y
expressed by MG63 cells were located in the cytosol and their membrane translocation
was PMA dependent, which was consistent with effects in other cells (Nishizuka et al.,
1995). PKCa and y membrane translocation in MG63 cells occured by 30 minutes of
PMA treatment. This was consistent with the conventional concept that cPKC activation
shows the rapid translocation of the enzyme from its inactive form in the cytosol to the
active state in the membrane. The role of PKCa and y in the regulation of cell function
is not clear. It was reported that PKCa was able to phosphorylate Raf-1 protein which is
associated with increased cell proliferation (Lisanti et al., 1994). PKCy has been
reported to phosphorylate several cellular proteins including: insulin receptor, EGF
receptor and vitamin D receptor (Dekker et al., 1994; Abeliovich et al., 1993).
Interestingly, our previous results (III of Chapter three) showed that PMA potentiated the
effect of 1,25D3 on the stimulation of the ALP activity in MG63 cells. We postulate that
the PKCa and y mediated pathways may be involved in this potentiation funtion and this
will be further tested.

58
nPKCs, 0 and 5 have a deleted C2 Ca ++ binding domain on their N-terminal
regions and do not require Ca++for their activation (Nishizuka et al., 1992).

All three

isoforms were expressed in human MG63 cells. PKCs was highly expressed in a
membrane-bound form in untreated cells with much less amount detectable in the cytosol.
Surprisingly, 30 minutes of PMA treatment obviously caused the PKCs translocation from
the cytosol to the membrane even though this isoform was already membrane-dominant.
How can this result be explained?

We postulate that membrane-bound PKCs may be an

active form and plays a role in maintaining basal cell function. This is consistent with the
suggestion that the membrane-bound PKCs may reflect cellular constitutive activity
(Kikkawa et al., 1989; Bazzi et al., 1988). The PKCs membrane translocation induced
by PMA means further activation of this isoform. Because this isoform showed a
constitutive activation in untreated cells, it is suspected that this isoform plays a role in
the ALP stimulation by PMA and 1,25D3 combination treatment in MG63 cells.

PKC0

was also highly expressed in the membrane of MG63 cells. It was reported that PKC0 is
present in most tissues (Baier et al., 1993; Chang et al., 1993) and that the activation of
this isoform is Ca++ independent. Activation of PKC0 did not require phosphatidylserine
and diacylglycerol, nor phorbol ester either (Nakamura et al., 1994; Nishizuka et al.,
1992). This was consistent with the present study which showed that PKC0 did not
respond to PMA. The possible explanation for this is that the membrane-bound PKC0 is
already in its active form. Alternatively, PKC0 activation does not require its
translocation to another compartment, which was reported by Grabarek et al. (1993).
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PKC5 was also expressed in MG63 cells. In contrast to PKCot, the recruitment of cytosol
PKC5 to the membrane by PMA appears to be a relatively slow event in MG63 cells
because a 30 minute PMA treatment had no effect on PKC8 translocation and a slight
increase of PKC5 protein in the membrane was seen at 24 hour of PMA exposure. This
elevated level of PKC5 by 24 hour of PMA treatment may reflect the increased protein
level and the mechanism is unknown.
aPKCA and i are highly expressed in brain and lung, but they are also seen in
many other tissues at lower levels (Nashizuka Y, 1995). In our experiment, PKCA, was
detectable in both cytosol and membrane of MG63 cells, and PKCi was mainly expressed
in the cytosol. Neither was affected by PMA treatment. This was consistent with other
reports that the extracellular signal for activation of aPKC enzymes remains unknown and
the activation of these enzymes is not affected by diacylglycerol, phorbol esters and Ca++
(Ways et al., 1992; Ono et al., 1989b). It is also consistent with the structural analysis
that this PKC group has lost the lipid binding domain on its partially truncated C 1
regulatory region (Liyanage et al., 1992). Functionally, the role of PKC A, is not known.
It is postulated that PKCi plays a role in the secretory response to nutrients (Selbie et al.,
1993).
A long term (24 hour) treatment with PMA was used to test whether different
isoforms were resistant to inactivation by proteolytic down-regulation ((Bomer et al.,
1992). In MG63 cells, PKC isoforms showed differential responses to down-regulation
by PMA at 24 hours. PKCot and y were more susceptible and were completely depleted in
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both cytosol and membrane after 24 hours PMA treatment. At this point, other PKC
isoforms were more resistant to proteolysis and did not show down-regulation of either
membranous or cytosolic fraction. Similar results have been reported in fibroblastic cells
(Borner et al., 1992a), but opposite results (down-regulation by PMA) were also
reported by others (Kishimoto et al., 1989; Schaap et al., 1990b).
Western blots can only show PKC protein level but not activity changes. Thus,
assaying protein kinase C activity provided another way to analyze the effect of PMA on
PKC translocation and activation. In our experiments, the activity assay was partially
parallel with Western blot protein levels which showed translocation of cytosol PKC to
the membrane with 30 minutes of PMA treatment and depletion of PKC from both
fractions with 24 hour PMA treatment. We postulate that this PKC activity reflects
isoform PKCa and y based on the following reasons: (a) there are more activators for
cPKCa and y than other PKCs, such as Ca++, DAG, phospholipid; (b) histone is a poor
substrate for nPKC (Schaap et al., 1989) and activators for aPKC are still unknown
(Waysetal., 1992). Therefore, it is postulated that cPKC expression and regulation
may play a major role in regulation of MG63 cell function.
In summary, we are the first to show the expression of seven PKC isozymes in
human MG63 osteosarcoma cells and to characterize their cellular distribution and
response to PMA. In MG63 cells, PMA showed a strong effect on PKCa, y and 8
activation and translocation from the cytosol to the membrane. So PKCa, y and 8 may be
functionally related to PMA-induced cellular functions in MG63 cells. PKCs and 9 in
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MG63 cells were expressed in a membrane-bound form and may function in maintaining
the cellular basal activity. The present study also provided a valuable model (MG63 cells)
for study of the PKC signal transduction pathway.
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V.

TGFB! AND PMA-ENHANCED 1,25-DIHYDROXYVITAMIN

D3 INDUCTION ON ALP ACTIVITY IS MEDIATED BY PKC-y,
BUT NOT PKC-a, IN HUMAN MG63 OSTEOSARCOMA CELLS

A.

Introduction
Alkaline phosphatase (ALP) is a bone differentiation marker, highly expressed by

osteoblastic cells (Rodan et al., 1984a). Hypophosphatasia is a disease in which a single
point mutation in the ALP gene results in poor bone mineralization (Weiss et al, 1988a).
ALP is thus functionally involved in both bone differentiation and mineralization. ALP
activity can by regulated by 1,25D3 in vitro. TGFBi, as an active component of a
regulatory cytokine and cell differentiation agent, dramatically enhanced the effect of
1,25D3 to stimulate ALP activity. The molecular basis for TGFBi potentiation of the
1,25D3 effects on ALP stimulation is unknown.

Our previous data showed that the

TGFBi effects on the 1,25D3 induction of ALP activity can be produced by adding both
factors sesquentially, i.e., TGFBi first and then 1,25D3 but not vice versa. These results
suggested that there were some interactions between TGFBi and 1,25D3, which were
mediated by the TGFBi signal transduction pathway. There are numerous studies
implicating the PKC signaling pathway in the actions of TGFBi in a series of cell types:
such as embryonic vascular smooth muscle cells, colon carcinoma cells and ovarian
granuloma cells (Wremi et al., 1993; Chakrabarty, 1992; Pennybacker et al., 1992).
Furthermore, 1,25D3 also was reported to activate PKC pathways affecting cell
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differentiation in many tissues (Bissonnett et al., 1995; Yen et al., 1993; Chang et al.,
1993). Studies of PKC pathways may reveal the interaction mechanism between the
locally produced growth factor TGFBi and the circulating hormone 1,25D3.
The protein kinase C (PKC) family is composed of a group of isoforms. So far at
least ten of them have been reported and each of them is assumed to play a different role
in transducing extracellular signals (Nishizuka et al., 1988). Now, the best known PKC
activator is phorbol myristate acetate (PMA). In a variety of cell types, PMA-induced
activation of PKC is associated with translocation of the enzyme from the cytosol to the
membrane fraction (Ganesan et al., 1992; Kikkawa et al., 1986). PKC is also activated
upon external stimulation by peptide hormones and growth factors (Nishizuka et al.,
1988). It has been shown that PKC plays a crucial role in regulation of cell growth and
differentiation (Lisanti et al., 1994; Dekker et al., 1994).

The two major PKC isoforms

expressed in MG63 cells were PKCa and PKCy (previous data). PKCa was reported to
phosphorylate Raf-1 and PKCy was shown to phosphorylate the EGF receptor and the
vitamin D receptor (Dekker et al., 1994; Abeliovich et al., 1993).
In the present study we postulated that there is an interaction between TGFBi and
1,25D3 in MG63 cells and that the PKC signal transduction pathway could mediate the
interaction involved in ALP activation by TGFBi and 1,25D3. The first and second parts
of our studies (Chapter Three and Four) provided evidence that PKC is functionally
involved in ALP stimulation by the combination of TGFBi and 1,25D3 in MG63 cells and
that MG63 cells expressed seven PKC isoforms. The specific aims of the present studies
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are to compare the known PKC activator, PMA, with TGFBi for their effects on 1,25D3
stimulated ALP activity in MG63 cells and compare the effects of PMA with TGFBi and
1,25D3 on PKCoc and y expression and activation.

B.

Results
In the present study, MG63 cells were treated with TGFBi, PMA and 1,25D3 and

the cell extracts were used for assay of ALP activity and ALP mRNA levels. Western
blots were employed for PKC activation assay using specific monoclonal PKC isoform
antibodies.
1. Evidence that PKC activation increases the 1,25D3 effect on ALP
stimulation
(1). Comparison of TGFBi and PMA effects on ALP activity in the presence of
1,25D3. TGFBi at 1 ng/ml or PMA at 10 '7 M alone had little effect on ALP activity
(Table 2). 1,25D3 alone significantly stimulated ALP activity to 300 % of control level
(P < 0.01). The combination of TGFBi and 1,25D3 increased ALP activity to 600% of
control. Like TGFBi, PMA combined with 1,25D3 increased ALP activity to 520% of
the control.
(2). Time course effect of TGFBi and PMA on l,25D3-stimulated ALP activity. A
72 hours time course experiment is shown in Figure 22. Ing/ml of TGFBi and 10 '7 M
PMA had little effect on ALP activity in MG63 cells. Treatment of MG63 cells with

65
1,25D3 alone, cell ALP activity was increased to two fold which was statistically
significant. Interestingly, when cells were treated by 1,25D3 plus either TGF13
(Figure 22A) or PMA (Figure 22B), the ALP activity response curve increased to 1200%
and 900% over the control, respectively. The peaks of maximum induction varied from
36 to 48 hours after treatments in different experiments.
(3). Comparison of dose response curves for combination-stimulated ALP activity.
At 48 hours, there was a dose-dependent increase of ALP activity when MG63 cells
were incubated with 1,25D3 plus different doses of either TGFBi (Figure 13 A) or PMA
(Figure 13B). TGFBi alone, from 0.1 to 1 ng/ml did not show any effect on ALP activity
and a similar result was seen with PMA treatment, 10 '9 to 10 '7 M. 1,25D3 increased
ALP activity to 200% of control at 48 hours (P < 0.01). TGFBi maximally increased ALP
activity to 2400% of control at Ing/mL in the presence of 1,25D3. The maximum effect
of 10 '7 PMA in the combination with 10 8 M 1,25D3 was only 540 % of the control level.

2. Effect of TGFBi and PMA on l,25D3-stimulated ALP mRNA level.
A Northern blot of ALP mRNA levels is shown in figure 23 A. The upper panel
shows the ALP mRNA which is a 2.4 kb band. The lower panel shows the methylene
blue stained 28S ribosomal RNA which was used to evaluate RNA loading. Compared
with control (lane 1), TGFBi at 1 ng/ml and PMA at 10 ‘7 M did not increase the
expression of the ALP mRNA band (lane 2 and 3). 1,25D3 at 10 '8 M increased the ALP
mRNA band density to 200% of control (lane 4). TGFBi in combination with 1,25D3

66
increased ALP mRNA levels to 800% of control (lane 5) and PMA plus 1,25D3 increased
ALP mRNA to 600% of control (lane 6). Densitometry scan data shows that the
increases of ALP mRNA by combinations of TGFBi plus 1,25D3 and PMA plus 1,25D3
were statistically significant (figure 23B).

3. Effect ofTGFfii, PMA and 1,25D3 on PKC translocation (activation).
(1) PKCa: Figure 24 shows the effects of TGFBi, PMA, 1,25D3 and their
combination on PKCa translocation after a 30 minute treatment. PKCa is an 82 kDa
protein predominantly located in cytosol of MG63 cells (lane 1, upper panel). Treatment
of cells with 10 -7 M PMA (lane 3) and its combination with 10 8 M 1,25D3 (lane 6) caused
PKCa translocation from cytosol (upper panel) to membrane (lower panel). No PKCa
bands were detectable in the membrane fraction of cells treated with TGFBi (lane 2),
1,25D3 (lane 4) or their combination (lane 5). Thus, TGFBi, 1,25D3 and their combination
had no effect on PKCa translocation in MG63 cells.
(2) PKCy: Figure 25 shows the effects of TGFBi, PMA, 1,25D3 and their
combination on PKCy translocation after a 30 minute treatment. PKCy is an 80 kDa
protein predominantly located in cytosol (not shown). 1 ng/ml TGFBi (lane 2),
10‘8 1,25D3 (lane 4) and the combination of TGFBi and 1,25D3 (lane 5) increased the
intensity of the membrane bound PKCy bands compared to control (lane 1). The darkest
PKCy bands on the membrane (lower panel) were in the samples treated with PMA (lane
3) and its combination with 1,25D3 (lane 6). Densitometry scan data is shown in figure
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25B. TGFpi, 1,25D3 and the combination of TGFPi plus 1,25D3 significantly increased
the PKC bands to about 200%, 220% and 300% over the control level.

C.

Discussion
ALP activity is a marker for osteoblast differentiation and can be increased by

1,25D3 in human MG63 cells (Bonewald et al., 1992). A previous study suggested that
1,25D3 regulated ALP activity through its genomic action (Hannah et al., 1994); i.e. by
increasing ALP mRNA transcription and stabilization (Kyeyune-Nyombi et al., 1991). In
the present study, we provide the evidence that the combination of TGFBi and 1,25D3
synergistically stimulated ALP activity but also increased ALP mRNA levels in MG63
cells. Because TGFBi alone had no effect on the induction of the ALP activity and ALP
mRNA, we postulate that the synergistic effect of TGFBi and 1,25D3 on ALP activity
was due to TGFBi action on the 1,25D3 signal pathway. Because our data also confirmed
that PKC was functionally involved in l,25D3-stimulated ALP activity in MG63 cells (III
of Chapter Three), we further tested if TGFBi effects on 1,25D3 function were related to
the PKC activation.
PMA is known to activate protein kinase C by mimicking the biological activity of
diacylglycerol (Nishizuka, 1988). Its positive role in regulation of cell differentiation has
been reported in a human leukemia cell line (Nagasawa et al., 1980) and the human U-2
osteosarcoma cell line (Ringbom-Anderson et al., 1992).

Thus, using PMA as a tool can

help to elucidate if PKC is involved in TGFBi and 1,25D3 action and how altering PKC
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activity can mediate the TGFBi enhancement of the effect of 1,25D3 on the ALP
activity.
In the present study, we found that PKC activation by PMA had no effect on basal
levels of ALP activity and ALP mRNA levels. This is consistent with previous
observations in MC3T3-E1 cells (Kozawa et al., 1989). However, PMA combined with
1,25D3 synergistically increased ALP activity to 540% of the control. We conclude that
the activation of PKC did not directly cause ALP gene activation but interacts with the
1,25D3 signaling pathway to potentiate 1,25D3 effects on ALP expression. Interestingly,
TGFBi had the samilar effects as PMA which did not effect basal levels of the ALP
activity and ALP mRNA, but synergistically increased both ALP activity and ALP mRNA
levels induced by 1,25D3. We hypothesize that TGFBi has effects on the PKC activation
in human MG63 cell line because the effect of TGFBi on the PKC activation was
observed in rat chondrocytes and human vascular smooth muscle cells (Wrenn et al., 1993;
Sylvia et al., 1994). The synergistic effect of TGFBi and 1,25D3 on ALP may be related
to the TGFBi-mediated PKC pathway activation. Surprisingly, cells expressed much
higher ALP activity in the combination of TGFBi with 1,25D3 treatment than in the
combination of PMA with 1,25D3, even though the concentration of both TGFBi and
PMA were saturated for maximal ALP induction in the presence of 1,25D3 (data not
shown).

Comparison of the Western blot data showed much higher PKCy activation by

the combination of PMA with 1,25D3 than that induced by the combination of the TGFBi
and 1,25D3. There are two alternative interpretations for these data, one interpretation is
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that PMA is not a native physiological PKC activator and cannot be hydrolyzed by
cellular protease. That is why PMA caused more PKC membrane translocation and
accumulation. TGFBi or 1,25D3 activated PKC through generation of DAG which is the
in vivo PKC activator and can be inactivated by DAG kinase inside the cells after PKC
activation (Nelsestuen et al., 1989; Kikkawa et al., 1989). This is the reason why the
PKCy bands which TGFBi and 1,25D3 induced was less strong than the one that PMA
induced, A second interpretation is that unlike PMA which works on the PKC pathway,
TGFBi may interact with 1,25D3 through multiple pathways, so the ALP activity in
TGFBi and 1,25D3 treatment would be higher than that of the PMA and 1,25D3
combination treatment.
PKC isozymes are homologous and share highly conserved domains. They differ
in tissue expression, subcellular distribution, substrate specificity, and activating cofactor
requirements, suggesting that they have different roles in regulating cell functions
(Nishizuka, 1992; Wetsel et al., 1992). In previous studies (Chapter Four), we showed
that MG63 cells expressed at least seven PKC isoforms and suggested that cPKCa and y
might play the major role in MG63 cell function regulation. Furthermore TGFBi and
1,25D3 did not show any effect on other PKC isoforms (data not shown). In the current
study we tested if PKCa and PKCy activation was affected by TGFBi and 1,25D3. We
have demonstrated for the first time that PKCy, but not PKCa, was involved in TGFBi
and 1,25D3 signaling pathways in MG63 cells. We suggested that TGFBi and 1,25D3
may act through a common PKCy pathway in MG63 cells and this pathway may be
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involved in their action on stimulation of ALP activity. The physiologic roles of specific
PKC isoforms remain poorly defined. PKCy was observed previously only in brain
extract (Nishizuka, 1995). Our study demonstrated for the first time that PKCy is also
present in human MG63 osteosarcoma cells. It was reported that PKCy is related to
VDR phosphorylation (Abeliovich et al., 1993) and VDR phosphorylation is related to
1,25D3 responsive gene activation (Darwish et al., 1993). Thus this could be one of the
mechanisms for TGFBi potentiation of 1,25D3 effects to increase alkaline phosphatase
activity in MG63 cells.
Further study is necessary to reveal the PKCy function in MG63 cells. Since VDR
plays a central role in l,25D3-stimulated osteoblast differentiation and ALP induction,
understanding the functional relationship between PKCy and the VDR phosphorylation is
very important. This will benefit the mechanistic study of TGFBi potentiation of 1,25D3
effects on ALP stimulation.
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VI.

TGFPi POTENTIATES 1,25-DIHYDROXYVITAMIN D3 -

INCREASED ALKALINE PHOSPHATASE ACTIVITY IN HUMAN
MG63 OSTEOSARCOMA CELLS BY INCREASING VDR mRNA,
VDR PROTEIN AND VDR PHOSPHORYLATION

A.

Introduction
Bone formation involves osteoblast proliferation and differentiation. Very little is

known about the regulation of human osteoblast differentiation which is characterized by
ALP activity, synthesis of type I collagen, and osteocalcin (Skjodt et al., 1985; Franceschi
et al., 1988; Kerner et al., 1989). The seco-steroid 1,25D3 is an important regulator of
bone cell differentiation in vitro and stimulates the expression of the above differentiation
markers of bone, especially ALP activity. Previous studies on normal human bone cells
in our laboratory (Wergedal et al., 1992) and on MG63 osteoblastic osteosarcoma cells
have demonstrated that the stimulation of ALP by 1,25D3 is markedly and synergistically
enhanced by TGFBi (Bonewald et al., 1992). Therefore, the focus of the present study
is to investigate how TGFBi potentiates the action of 1,25D3 to synergistically stimulate
ALP activity. TGFPi which is present in large quantities in human bone matrix (Seyedir
et al., 1986), has been known as a bone cell differentiation agent. It works most
potentially and effectively by interacting with other factors to modulate their effects
(Sporn et al., 1986). The remarkable increase in ALP by TGFPi and 1,25D3 is due to a
synergism between the individual effects of the two factors. The objective of this paper
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was to extend these observations with respect to revealing the mechanisms responsible for
this interaction. The significance of studying this interaction is that the effects of
TGFBi and 1,25D3 to increase ALP activity is much greater than any other agent or the
combination of agents reported in the past. Thus, these two agents could have a major
effect on the regulation of bone cell differentiation.
It is well documented that 1,25D3 has nuclear receptors (VDR) and that the
genomic effect of this hormone acts by forming a ligand-receptor complex which serves
as a transcription factor, binding to the VDRE (VDR response element) sequence in the
promoter region of the 1,25D3 responsive gene (Ross et al., 1993). The VDR is a
member of the steroid hormone receptor superfamily which includes the receptors for sex
hormones, progesterone, glucocorticoid, thyroid hormone and retinoic acid (Evans et al.,
1988; Haussler et al., 1988). Most receptors in this superfamily are phosphoproteins and
can be phosphorylated by kinases. Steroid receptors which can be phosphorylated are
progesterone receptor (Dougherty et al., 1982), glucocorticoid receptor (Housley et al.,
1983), thyroid receptor (Goldberg et al., 1988) and VDR itself (Jurutka et al., 1993).
It was reported that 1,25D3 increases the phosphorylation of VDR (Jurutka et al., 1993)
and this phosphorylated VDR can then increase cell responses to 1,25D3 (Evans et al.,
1988). Regulation of active receptor protein level, such as the up-regulation of VDR
mRNA and VDR receptor number, is also thought to be an important mechanism by
which target cell responsiveness to hormones is modulated (Staal et al., 1994). Several
factors, including the action of 1,25D3 itself, glucocorticoids, and retinoic acid; have
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been demonstrated to modulate VDR mRNA and protein levels (Pan et al., 1987; Chen
et al., 1986b; Chenetal., 1985).
The MG63 cell line is derived from a human osteoblastic osteosarcoma. These
cells have been shown to respond to 1,25D3 by increasing ALP activity, collagen type I
synthesis and osteocalcin production (Franceschi et al., 1985; Franceschi et al., 1987;
Franceschi et al., 1988). In this report, we investigated the mechanism of the TGF(3i
effects on the action of 1,25D3 to increase ALP activity in the MG63 cell line by
measuring ALP mRNA expression, VDR mRNA induction, VDR protein level, and VDR
phosphorylation. Our results suggested that TGF|3 enhancement of ALP induction by
1,25D3 is regulated at least partially by increasing VDR mRNA, VDR protein and VDR
phosphorylation.

B.

Results
In the present study, we tested the effect of TGFpi and 1,25D3 on VDR mRNA,

VDR protein, and VDR phosphorylation; as well as ALP mRNA level in MG63 cells. The
results from time course experiments provided evidence that the TGFpi mediated 1,25D3
effect on ALP activity was partially associated with its effect on VDR.
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1. Evidence for the synergistic effects of TGFfii and 1,25D3 on ALP activity
and mRNA level.
(1) Dose dependent effect of 1,25D3 on ALP activity.

Incubation of MG63

cells with 1,25D3 at doses of 10 '9 to 10 ‘7 M caused an increase of ALP activity of
MG63 cells at 48 hours (Figure 26). The maximum effect was 300 % of the control
level (P < 0.01) with the optimal dose at approximately 10 ‘8 M .
(2) Time course of TGF(3i effect on l,25D3-stimulated ALP activity. The time
course effects of TGFpi (Ing/mL), 1,25D3 (10 "8 M) and both in combination on ALP
activity are shown in Figure 22A. TGF(3i alone had little effect on ALP activity within
3 days. In contrast, 1,25D3 increased the cellular level of ALP activity at 36 hours to
about 200 % over the control.

The combination of TGFpi and 1 ,25D3 showed a

synergistic effect on ALP activity with a maximum increase of 1200 % of the basal level.
(3) Dose response effect of TGFBi on l,25D3-stimulated ALP activity. The dose
response curve showed that TGFpi alone at doses from 0.1 ng/ml to 1 ng/mL had a
minimal effect on MG63 cell ALP activity in a 48 hour incubation (Figure 27). Co
incubation of TGFPi with 10 "8 M 1,25D3 caused a synergistic effect on stimulation of
ALP activity with the maximum response at a concentration of 1 ng/ml of TGFPi at
48 hours. The maximum response was 2200 % of the control level.
(4) Time course effect of TGFPi and 1,25D3 on ALP mRNA level. A 36 hour
time course study is shown in Figure 28. Fig. 28A showed a representative Northern
Blot result. TGFPi at 1 ng/mL alone had no effect on ALP mRNA stimulation in MG63
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cells. 1,25D3 alone increased ALP mRNA from 9 to 24 hours. The combination of TGF(3
with 1,25D3 greatly stimulated ALP mRNA level at 12 and 24 hours (Figure 28A). Figure
28B shows the densitometry scan results from two separate experiments. TGFBi had no
effect on ALP mRNA but 1,25D3 appeared to increase ALP mRNA about 200 % of the
control, which was not statistically significant. The combination of TGFBi and 1,25D3
significantly increased ALP mRNA about 800 % of control at 24 hours. These data
demonstrate that TGFpi alone does not enhance ALP mRNA but can potentiate 1,25D3
stimulated ALP mRNA induction.

2. Evidence that TGFfii and 1,25D3 affect VDR mRNA, VDR protein and
VDR phosphorylation
(1) Time course effect of TGF|3i and 1,25D3 on VDR mRNA level. VDR mRNA
levels were measured in a 36 hours time course experiment (Figure 29). Figure 29A
showed a representative Northern Blot analysis result. VDR mRNA levels were increased
by TGFpi alone or the combination of TGFfL with 1,25D3 at 3 hours. After 3 hours,
VDR mRNA levels decreased with time but remained above basal level up to 36 hours.
1,25D3 gradually increased VDR mRNA levels after 24 hours of treatment.
Densitometric results from two separate experiments are shown in figure 29B. TGFBi
alone and its combination with 1,25D3 both increased VDR mRNA levels to 300 % and
450 % above the control level at 3 hours which were statistically significant. VDR mRNA
level in the 1,25D3 treatment did not change during the first 12 hours of incubation but
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was increased 200 % of control at 24 hours. Therefore TGFpi has a direct effect on the
VDR mRNA level which exhibited a different time-dependent curve than 1,25D3
treatment. The VDR mRNA level of TGFBi and 1,25D3 combination treatment was
much higher than either TGFBi alone or 1,25D3 alone.
(2) Effect of the combination of TGFBi with 1,25D3 on VDR protein levels.
Because our data showed the strong VDR mRNA induction at 3 hours by TGFB and its
combination with 1,25D3, we wanted to know if this increased VDR mRNA level is
associated with increased VDR protein. Figure 30A shows a TGFBi and 1,25D3
combination effect on VDR protein levels at 2, 4, 6, and 12 hours compared with
untreated controls at 2 and 12 hours. VDR protein migrates as a 55 kD molecular mass
band. The combination of TGFBi with 1,25D3 greatly increased VDR protein levels at
4 and 6 hours. Densitometric scanning results from two separate experiments revealed
that the combination of TGFBi and 1,25D3 significantly stimulated VDR protein levels at
4 and 6 hours with the peak about 300 % over the control level at 6 hours (Figure 3OB).
Similar results were seen in the treatment group with TGFBi alone (data not shown).
(3) Effect of TGFpi and 1,25D3 on VDR phosphorylation. The effects of TGF(3i,
1,25D3, and the combination of both TGFpi and 1,25D3 on VDR phosphorylation in the
MG63 cell line were examined by determining 32P-orthophosphate incorporation into
the VDR after immunoprecipitation of phosphorylated VDR. As shown in Figure 31 A,
TGFBi, 1,25D3 and the combination all increased the phosphorylation of a 55 kDa protein
(VDR) band at 2 hours of treatment. Figure 3 IB shows the results of the densitometry
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scans of the Northern blots from at least two samples. After two hour treatments with
TGFBi at 1 ng/ml and 1,25D3 at 10‘8 M, VDR phosphorylation was increased to 700 %
and 300 % of the control level, respectively. The combination of TGF(3i and 1,25D3 had
an additive effect increasing VDR phosphorylation to 1000 % of control value. These
results strongly suggested that TGF(3i potentiated 1,25D3 induction of ALP activity in the
MG63 cells at least partially due to increasing VDR phosphorylation.

C.

Discussion
In the present study, 1,25D3 alone or in combination with TGFBi increased ALP

activity in MG63 cells, which was directly related to an increase in ALP mRNA levels
because the time course of maximum ALP mRNA stimulation at 24 hours closely
preceded the increase in ALP activity at 48 hours. Thus it is clear that the synergistic
effect on ALP activity increased by 1,25D3 in combination with TGFBi was associated
with the increased level of ALP mRNA. The molecular basis of this ALP induction may
be due to increased ALP gene transcription and stabilization (Kyeyune-Nyombi et al.,
1991) or kinetically via an increased ALP Vmax (Jeng et al., 1994). With respect to
ALP gene regulation by 1,25D3, it is conceivable that there may be a vitamin D response
element (VDRE) in the promotor region of the ALP gene, which responds to 1,25D3 for
the transactivation. So far the ALP gene promoter region is not fully sequenced, so it is
impossible to identify such elements.
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The signal transduction pathways of steroid hormones are very well documented
and all of them have nuclear receptors which mediate their genomic function.

It is

reported that the genomic effect of 1,25D3 on the regulation of cell proliferation and
differentiation is mediated by VDR (Norman et al., 1992). Osteoblast responsiveness to
1,25D3 is positively related to VDR numbers (Chen et al., 1986a; Chen et al., 1986b) and
it was suggested that receptor up-regulation can increase the magnitude and sensitivity of
cellular responses to 1,25D3. Staal et al.(1994) reported that TGFBi maximally increased
VDR induction at 6 hours in MG63 cells as measured by receptor binding assay. The
present study demonstrated that TGFBi or TGFBi combined with 1,25D3 not only
maximally increased VDR protein levels at 4 to 6 hours but also increased VDR mRNA
levels as early as 3 hours. The time difference between maximum VDR mRNA induction
and ALP mRNA induction by TGFBi in combination with 1,25D3 suggests that the upregulated VDR mRNA and VDR protein levels induced by TGFBi exert certain functions
to potentiate the 1,25D3 effect on ALP activity. TGFBi increased VDR mRNA
transcription and VDR protein could directly contribute to the remarkable ALP induction
by the synergistic effects of TGFBi and 1,25D3. We suggest that this elevated VDR
protein level will increase cell response and sensitivity to 1,25D3. We have evidence that
1,25D3 was required to be in contact with cells for at least 6 hour to induce maximum
ALP activity (data not shown). Therefore, the period for the VDR induction by TGFBi
and the period for the ALP stimulation by 1,25D3 were closely matched. The mechanism
for TGFBi to activate VDR gene expression is not clear, because at this time, there was no

79
TGFBi response element (TRE) detected in the known 115 nucleotides of the partially
sequenced promoter region of the human VDR gene (Baker et al., 1988). Further
investigations are needed.
The present study is the first to demonstrate that TGFBi alone or in combination
with 1,25D3 can increase VDR phosphorylation.

The phosphorylation could be detected

as early as 15 minutes of TGFBi treatment (data not shown). The increased VDR
phosphorylation is consistant with the report that the phosphorylation of nuclear proteins
is an important event for TGFBi action (Kramer et al., 1991). The functional state of
VDR can be regulated by phosphorylation and is post translationally phosphorylated at
serine 205 by Casein kinase or serine 51 by protein kinase C in vitro (Hsieh et al., 1991;
Hilliard et al., 1994; Jurutka et al., 1993). The phosphorylation of the VDR was
dependent on the presence of 1,25D3 (Jones et al., 1991) and has been shown to be an
early event in 1,25D3 action (Jurutka et al., 1993). So VDR phosphorylation plays an
important role in transmitting the 1,25D3 signal and transactivating vitamin D responsive
genes. It is postulated that the increased VDR phosphorylation induced by TGFBi or the
combination of TGFBi plus 1,25D3 at 15 minutes to 2 hours played an important role in
the synergistic induction of ALP activity by the combination of both TGFBi and 1,25D3.
The mechanism of VDR phosphorylation by TGFBi is unknown but recent studies
provided evidence that TGFBi can activate PKC signal transduction pathway (Howe et
al., 1991; Shibanuma et al., 1992) and phosphorylate several nuclear proteins (Kramer et
al., 1991). Furthermore, the TGFBi type II receptor has functional serine/threonine
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protein kinase activity on its intracellular domain (O’Grady et al, 1992; Lin et al., 1992).
Combined with our previous finding (IV in Chapter three) which showed TGFBi and
1,25D3 activated PKCy in MG63 cells, we postulate that this PKC kinase cascade may
play a role in TGFBi induced VDR phosphorylation. We need further studies to test our
hypothesis.
In conclusion, TGFBi potentiates the action of 1,25D3 to increase cellular levels
of ALP activity by stimulating an increase in VDR mRNA levels, VDR protein levels and
VDR phosphorylation. Further study should be done to identify: (1) if there are TGFB
response elements on the promoter region of the VDR gene; (2) if there are VDRE
sequences on the promoter region of the ALP gene; (3) if there is a functional relationship
between VDR modification by TGFBi and synergistic stimulation of ALP by the
combination of TGFBi and 1,25D3; (4) if hVDR phosphorylation is directly related to an
increase in DNA binding and gene transactivation. Together, our results illustrate the
interaction between TGFBi and 1,25D3 at the level of the VDR and emphasize how a
locally produced growth factor, TGFBi assists the circulating hormone , 1,25D3 in
regulation of osteoblast differentiation.

CHAPTER FOUR
VII. SUMMARY, CONCLUSIONS AND MODEL
A.

Summary
1. The PKC pathway is functionally involved in ALP stimulation by 1,25D3 and the

combination of TGFBi plus 1,25D3.
2. The human MG63 osteosarcoma cell line expresses at least seven protein kinase
C isoforms which have different cellular localizations and responses to PMA. The PKCp
was not detectable.
3. TGFBi and 1,25D3 caused PKCy translocation from cytosol to the membrane.
4. In the MG63 cells, the increased ALP activity induced by 1,25D3 and the
combination of TGFBi plus 1,25D3 was associated with an increase in alkaline
phosphatase mRNA.
5. TGFBi and the combination of TGFBi with 1,25D3 increased VDR mRNA,
VDR protein level and VDR phosphorylation.

B.

Conclusions
1. Activation of PKCy is a potential signal transduction pathway for TGFBi and

1,25D3 to increase ALP activity.
2.Through increasing VDR mRNA, VDR protein level, and further increasing
VDR phosphorylation, TGFBi potentiated l,25D3-induced ALP activity in the MG63
cells.
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C.

Proposed model
Based on our findings, we postulate that there may be TGFBi response elements

(TRE) in the promoter region of the VDR gene and a VDRE site in the promoter region
of the ALP gene. We further propose the following model to show how TGF13
potentiates the increase of ALP activity induced by 1,25D3 in MG63 cells (Figure 32). In
this model, TGFBi acts in two separate pathways to interact with 1,25D3. In the first
one, TGFBi binds to its receptors which have serine/threonine kinase domains. The
active form of kinase then activate PKCy which in turn initiates a phosphorylation
cascade chain. At this step, TGFBi transduces its signal to the nucleus and transactivates
VDR gene, which has TGFBi response elements. The final response is the increase in
VDR mRNA and VDR protein levels. This up-regulation of VDR mRNA and protein
increases the potential cell response and sensitivity to 1,25D3. The second pathway is
TGFBi induced VDR phosphorylation. Phosphorylated VDR was reported to have
higher ability for the gene transactivation (Jurutka et al., 1993). An increase of both
VDR phosphorylation and VDR protein level escalate the cell response to 1,25D3.
Sequentially, the ALP activity is increased.
Further studies are needed to investigate: (1) if there are TGFBi response elements
in the promoter region of the VDR gene, (2) if there is a VDRE in the promoter region
of ALP gene, (3) the effect of VDR modification by TGFBi on the synergistic stimulation
of ALP by the combination of TGFBi and 1,25D3, (4) if phosphorylation of hVDR is
directly related to an increase of DNA binding and gene transactivation.

CHAPTER FIVE
VIII.
A.

APPENDIX

Alkaline phosphatase assay solution
1. 0.1% Triton X-100
2. Alkaline phosphatase reaction buffer: 0.01 M p-nitrophenol phosphate, 1 mM

MgCl2, and 0.015 M Na2C03, pH 10.3.

B.

Northern blot solutions
1. cDNA labeling mix: 1MHEPES, pH 6.6, 0.3 M 2-mercaptoethonal, 15 units

of hexanucleotides, 0.2 mM each dNTP (dATP, dGTP and dTTP), 0.025 M Tris-HCl,
pH 8.0, 2.5 mM MgCl2 (Feinberg et al., 1983).
2. Deionized formamide: Formamide was melted at room temperature and 50 ml
was deionized with 5 g AG501 x 8 resin (BioRad) by stirring for 30 minutes at room
temperature. The solution was filtered twice with Whatman #1 paper, aliquoted and
stored at -20 °C (Ausubel et al., 1994).
3. Denhard 50 X stock: 1% ficoll, 1% polyvinylpyrrolidone, 1% bovine serum
albumin. The solution was then filtered through a disposable 0.22 pm Nalgene filter
(Ausubel et al., 1994).
4. DEPC water: 0.1% diethyl-pyrocarbonate was added to double-distilled water
for at least one hour. The treated water was then autoclaved.
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5. Methylene blue solution: 0.02 % methylene blue and 0.3 M sodium acetate, pH
5.5, stored in a dark bottle.
6. 10 X MOPS: 0.2 M 3-(N-morpholino) propanesulfonic acid, 5 mM sodium
acetate, 5 mM EDTA, pH 7.0 (Ausubel et al., 1994).
7. Northern sample loading buffer: 720 pi deionized formamide, 320 pi 10 X
MOPS, 260 pi formaldehyde solution (37 % stock solution), 100 pi glycerol, 4 mg
bromophenol blue, 4 mg xylene cyanol and 100 pi DEPC water (Ausubel et al., 1994).
8. 20XSSPE: 3.6MNaCl, 0.03 M NaH2P04, 0.02 M EDTA, pH 7.4 (Ausubel
et al., 1994).
9. 20 X SSC: 3.0 M NaCl and 3.0 M sodium citrate, pH 7.0 (Ausubel et al.,
1994).
10. TENS: 0.1 MNaOH, 0.01 M Tris-HCl, pH 8.0, 1 mM EDTA and 0.1 %
SDS.
12. 10XTMDSE: 0.01 M Tris-HCl, pH 7.6, O.lMMgCh, 0.05 MDTT,
1 mM spermidine and 1 mM EDTA (Ausubel et al., 1994).

C.

Protein kinase c assay solution
1. Buffer A: 20 mM Tris-HCl, pH 7.4, 1 mM EGTA, 2 mM EDTA, 0.5 mM

Benzamidine, 5 mM P-mercaptoethonal, 0.5 mM phenylmethylsulfonyl fluoride (PMSF),
10 mg/1 Leupeptin.
2. Buffer B: 0.3% Triton X-100 in Buffer A.
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3. Elution buffer: 150 mM NaCl in Buffer A.
4. Reaction buffer: 20 mM Tris-HCl, pH 7.6, 20 mM MgCl, 2 mM CaCl2, 1 mM
EGTA, 2 mM EDTA, 0.5 mM Benzamidine, 5 mM 2-mercaptoethanol, 0.5 mM PMSF, 5
mg/1 leupeptin, 5 pg/ml 1,2-diolein, 200 pg/ml phosphatidylserine, 20 pM cold ATP,
24 pM [y-32p] ATP and 200 pg/ml Histone Ha.

D.

Western blot solutions
1. Native extraction buffer: 10 mM Tris-HCl, pH 7.4; 150 mM NaCl, 1 mM

EGTA, ImMEDTA, 10 mM sodium molybdate, 20mMNaF, 0.5 mM PMSF,
1 pg/ml leupeptin, 1 pg/ml aprotinin and 2 pg/ml pepstatin A.
2. Denature gel buffer: 10 mM Tris-HCl, pH 7.4, 150 mM KC1, and 0.5% SDS.
3. Laemmili sample buffer: 125 mM Tris-HCl, pH 6.8, 10% glycerol, 1% SDS,
1.25 % 2-mercaptoethanol.
4. Transferring buffer: 25 mM Tris-HCl, pH 8.3, 20% methanol and 192 mM
glycine (Towbin et al., 1979).
5. TBS-T blocking buffer: 10 mM Tris-HCl, pH 7.4, 0.05% sodium azide,
150 mM NaCl, 0,05% Tween 20.
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E.

Radiolabeling of VDR and immunoprecipitation solutions
1. PBS washing buffer: 9.1 mM dibasic sodium phosphate, 1.7 mM monobasic

sodium phosphate, 150 mM sodium chloride, 3 mM potassium chloride, and 10 mM
sodium molybdate.
2. Denature extraction buffer: 10 mM Tris-HCl, pH 7.4, 10 mM sodium
molybdate, 0.5% SDS.
3. Immunoprecipitation buffer (2 X): 20 mM Tris-HCl, pH 7.4, 300 mM NaCl,
2 mM EDTA, 2 mM EGTA, 20 mM Na molybdate, 40 mM NaF, 1 mM PMSF,
1 pg/ml aprotinin, 1 pg/ml leupeptin, 2 pg/ml pepstatin, 2% Triton X-100, and 1%
NP40.
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Figure 1. Schematic illustration of the structure of the large latent TGFBi complex. This
complex is composed of mature TGF-pi, Pi-LAP and LTBP. Adapted from Miyazono et
al., 1993.
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Figure 2. Vitamin D structure and synthesis. The bond between C9 and CIO of 7dehydrocholesterol is broken by UV light and the product is named cholecalciferol
(Vitamin D3). Adapted from Mathews et al., 1990.
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Figure 3. The vitamin D endocrine system. Vitamin D metabolism involves two
sequential hydroxylations that produce the active hormonal form of the vitamin D3,
namely 1,25D3. These sequential hydroxylation reactions occur in separate tissues. A 25hydroxylase in liver first converts vitamin D3 into 25(OH)D3 and a 1-hydroxylase in kidney
hydroxylates the C-l position of 25(OH)D3 to generate the active form of 1,25D3. The
1-hydroxylase in kidney is controlled by hormonal regulation. The active form of vitamin
D3, l,25(OH)2D3, can be further catalyzed to a less active forms, such as l,24,25(OH)
2D3. l,24,25(OH) 3D3 is sub sequentially oxidized and finally becomes calcitroic acid.
Adapted from MacDonald et al., 1994.
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Figure 4. Transcriptional control of the rat osteocalcin gene by vitamins A and D. In
this model, 1,25D3 binds to the VDR and promotes its interaction with unliganded
retinoid X receptor (RXR) or receptor accessory factors (RAFs). The VDR-RXR
heterodimer is the functional transcription factor and it binds to the VDRE and
transactivates the vitamin D responsive gene. 9-cis retinoic acid may induce RXR
homodimer formation or RXR interaction with other receptors, therefore, diverting RXRs
away from vitamin D-mediated pathways. Adapted from MacDonald et al., 1993.
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Figure 5. Proposed model of genomic action of 1,25D3. Generic target cell generates
biological responses under the effect of 1,25D3 genomic activation and repression. S,
1,25D3; R, the nuclear 1,25D3 receptor (VDR); DBP, the plasma vitamin D binding
protein. Adapted from Bouillon et al, 1995.
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Figure 6. Schematic representation of N-terminal regulatory domain of PKC isoforms.
The structure of PKC consists of a single polypeptide chain containing four conserved
regions (C) and five variable regions (V). The N-terminal half containing Cl, C2, VI and
V2 constitutes the regulatory domain that interacts with PKC activators, such as Ca++,
phospholipid, DAG or Phorbol esters. The nPKC subfamily members are Ca++independent and lack the C2 domain. The aPKC subfamily members are apparently
independent of DAG, and phorbol esters as well as Ca++ due to the missing half of domain
Cl. Adapted from Akimoto et al., 1994.
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Figure 7. Hypothetical representation of signaling pathways for PKC activation. The
phosphatidylinositol 4,5-bisphosphate (PIP2) is a membrane storage form for two second
messengers. Ligand binding to the receptor will stimulate a G-protein-mediated
mechanism to activate the phospholipase C (PLC), which in turn cleaves PIP2 to yield
inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) Both products can act as
second messengers stimulating calcium release from its intracellular stores and activating
PKC. Adapted from Nishizuka, 1995.
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Figure 8. Schematic representation of the human liver/bone/kidney type alkaline
phosphatase gene and two types of mRNA. (A) Bone specific mRNA generated from the
chromosomal gene by alternative usage of the bone specific leader exon IB. (B) Structure
of liver/bone/kidney-type alkaline phosphatase gene. Exons are shown as open rectangles
with their respective numbers. There are total of 12 exons encoding the ALP protein. (C)
Liver-specific mRNA generated from the chromosomal gene by usage of the exon 1L.
Adapted from Sato et al., 1994.

103

21Sbp
A 5

UGCUCCCACGCGCUUGUGCCUGGA

v

IB /

CUUACUAACUCCUUAGUGCCAG

GAUU
T

2

11

'3

4 5

67

S

9

1011

12

-HHHK]—HHB-D—

B

\

,

3'i

\

\

i
i

\

\
\

i

\ I

M

C iS’

GGUGUUAUAUUGGAAUGAGUGAGUG

GAUU

CUUACUAACUCCUUAGUGCCAG-

'

S.

J

216bp
J

3'

104

Figure 9. Schematic illustration of the strategy for PKC pathway study. 1,25D3 can
increase the ALP mRNA level and ALP activity. TGFpi potentiates this 1,25D3 effect.
Using specific PKC pathway activator or PKC blockers, we can study if the PKC
pathway is functionally involved in ALP induction by both TGF(3i and 1,25D3.
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Table 1. Effect of Staurosporine on TGFBj and
1,25D3 stimulated ALP activity in MG63 cells
ALP Activity (%)
Control
0

ST (0.5 nM)

100±6.9
105±7.5

TGFBj 1 ng/ml
102±6.7
98±7.9

1,25DS * M
16fcfc6.5*
130±8.7b

TGFBj+I^5D3
850±79*
165±15*, b

Results are expressed as % of untreated control ± SD from at least six replicates.
* p<0.05 compared with untreated control,
b p<0.05 compared with staurosporine treatment alone.
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Figure 10. Effect of Staurosporine on l,25D3-stimulated alkaline phosphatase activity in
the presence of different doses of TGFBi. Cells were cultured in serum-free medium with
different doses of TGFBi and 0.5 nM staurosporine in the presence or absence of 1,25D3
at 10 8 M. The alkaline phosphatase activity was determined as described under
“Materials and Methods”. Data are mean ± SD of six replicates. * P <0.05 and ** p <
P < 0.01 compared with the TGFBi plus 1,25D3
0.01 versus the untreated control,
treatment.
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Figure 11. Staurosporine dose dependent inhibitory effect on TGFBi and 1,25D3stimulated alkaline phosphatase activity. Cells were cultured in serum free medium and
pretreated with different doses of staurosporine for 30 minutes, followed by addition of
TGFBi and 1,25D3 for 48 hours. The alkaline phosphatase activity was determined as
described under “Materials and Methods”. Data are mean ± SD of six replicates.
P < 0.01 compared with
* P < 0.05 and ** P < 0.01 versus the untreated control,
the combination of TGFBi plus 1,25D3 or 1,25D3 alone treatments.
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Figure 12. Effect of staurosporine (ST) on TGFBi and l,25D3-stimulated alkaline
phosphatase mRNA level. Northern blot of alkaline phosphatase mRNA level was
studied. The MG63 cells were cultured in serum free medium and treated with 0.5 nM
staurosporine, 1 ng/ml TGFBi, 10 -8 M 1,25D3 or their combination as shown in the
figure. After a 24 hour treatment, the cells were extracted as described under “Material
and Methods”. The mRNA bands of alkaline phosphatase are shown in the upper panel
and 28 S ribosomal RNA bands in the lower panel which were used to normalize the total
RNA loading (Figure 12A). The densitometry scan results are shown in Figure 12B.
Data are mean ± SD of at least two separate experiments. ** P < 0.01 vs the untreated
control. a P < 0.01 compared with the combination of TGFBi plus 1,25D3 treatment.
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Table 2. Effect of TGF6l5 PMA and both in combination on
1,25D3 stimulated ALP activity in MG63 cells
ALP Activity (%)
0
Control
1,25D3 10 ’M

TGFBj 1 ng/ml

100±9.7 101±14
300±34 * 650±60** b

PMA10 7M

TGFB^PMA

118±7.6
520±27**b

290±35*
1440±110**b

Results are expressed as % of untreated control ± SD from at least six replicates.
* P < 0.05 vs control
** P < 0.01 vs control.
b P< 0.01 compare with 1,25D3treatment alone.
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Figure 13. Dose effect of TGFBi and PMA on l,25D3-stimulated alkaline phosphatase
activity. Cells were pretreated with either different doses of TGFBi or PMA for 30
minutes in serum free medium and then 1,25D3 was added to the medium. The alkaline
phosphatase activity was determined as described under “Materials and Methods”. Data
are mean ± SD of six replicates. * P < 0.05 and ** P < 0.01 versus the untreated control.
a P < 0.01 compared with the 1,25D3 treatment alone.
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Figure 15. Subcellular distribution of the PKCy and its response to PMA. Description
same as Figure 14.
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Figure 16. Subcellular distribution of the PKC5 and its response to PMA.
same as Figure 14.
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Figure 17. Subcellular distribution of the PKCs and its response to PMA. Description
same as Figure 14.
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Figure 18. Subcellular distribution of the PKC0 and its response to PMA. Description
same as Figure 14.
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Figure 19. Subcellular distribution of the PKCA, and its response to PMA. Description
same as Figure 14.

127

30 minutes treatment

PKCX

Cytosol

Membrane

24 hour treatment

VKCX

Cytosol

Membrane

128

Figure 20. Subcellular distribution of the PKCi and its response to PMA. Description
same as Figure 14.
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Figure 21. Effect of PMA on PKC activation and redistribution. The experiment was
initiated by replacing the culture medium by fresh pre-equilibrated medium lacking or
containing PMA at 10 '7 M at zero time. Cytosolic and membrane fractions were prepared
as described under “Material and Methods”. Protein kinase C activity is expressed as
percent of control. Data shows mean ± SD of six replicate cultures. Figure 21A shows
that the PKC translocated to the membrane with PMA treatment. Figure 2IB shows
down-regulation of cytosol PKC by PMA.
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Figure 22. Time course effect of TGFBi and PMA on 1,25D3-stimulated alkaline
phosphatase activity. Subconfluent MG63 cells were treated with 1 ng/ml TGFBi, 10 '7 M
PMA, and 10 '8 M 1,25D3. The alkaline phosphatase activity was measured as described
under the “Materials and Methods”. The alkaline phosphatase activity is expressed as
percent of the control value. Figure 22A shows the effect of TGFBi, 1,25D3 and their
combination on alkaline phosphatase activity. Figure 22B shows the effect of PMA,
1,25D3 and their combination effects on alkaline phosphatase activity. Each point
represents the mean ± SD of specific alkaline phosphatase activity of six replicates. Data
are representative for at least three independent experiments. * p < 0.05 vs the untreated
control. ** p < 0.01 vs the untreated control. a p < 0.01 compared with the 1,25D3
treatment alone.

133

A.
1500

a

**
~ *• TGFfi) Ing/ml
1,25^0 10^M
TGFB +1,25D

O

^

1000

3

i

o

O

a

**

a

**

**-

O

r'
5oo
Q.

*

<

*
*
i------- *--------- * **

o
o

12

24

36

48

60

72

Time (hr)

B.
1200

-7

a

- *• PM A 10 M

ife *

a

**

O

1,25q

M

♦3

o 800

a

o
O

cl

**

a

g.

PMA+1,25D3
a

■k *

400

**
*

<

I

x

*

-Jr-*“=■ 4

x

0
0

12

JL

x

24

X

X

36

48

60

Time (hr)

72

84

96

134

Figure 23. Effect of TGFBi and PMA on l,25D3-stiniulated alkaline phosphatase mRNA
level. Northern blot of alkaline phosphatase mRNA level was studied. The MG63 cells
were cultured in serum free medium and treated with 1 ng/ml TGFBi, 10 '7 M PMA, 10 8
M 1,25D3 or their combination as shown in the figure. After 24 hour treatment, the cells
were extracted as described under “Materials and Methods”. The mRNA bands of
alkaline phosphatase were shown in the upper panel and 28 S ribosomal RNA bands in the
lower panel which were used to normalize the total RNA loading (Figure 23 A). The
densitometry scan results were shown in Figure 23B. Data are mean ± SD of at least two
separate experiments. ** P < 0.01 vs the untreated control.
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Figure 24. Effect of TGFfii, PMA and 1,25D3 on PKCa translocation. Subconfluent
MG63 cells in 100 mm dishes were treated with TGFBi, PMA and 1,25D3 for 30 minutes.
The cytosol and membrane were separated and submitted to Western blot as descripted in
“Materials and Methods”. The upper panel shows the PKCa level in the cytosol and the
lower panel shows PKCa level in the membrane. The treatments were vehicle, TGFBi
at 1 ng/ml, PMA at 10 7 M, 1,25D3 at 10 8 M, TGFBi combined with 1,25D3 and the
PMA combination with 1,25D3. The PKC activation was expressed as translocation of
PKCa protein from the cytosol to the membrane.
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Figure 25. Effect of TGFBi, PMA and 1,25D3 on PKCy translocation. The description is
the same as for Figure 24. Figure 25A showed the Western blot result and Figure 25B
shows the densitometry scan result of membrane bound PKCy bands. * P < 0.05 and ** P
<0.01 compared with the untreated control.
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Figure 26. Dose effect of 1,25D3 on specific alkaline phosphatase activity. MG63 cells
were treated with different doses of 1,25D3 in serum free medium for 48 hours. The
alkaline phosphatase activity was determined as described in “Materials and Methods”.
Data are expressed as mean ± SD of six replicates. * P < 0.01 compared with untreated
control.
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Figure 27. Dose dependent effect of TGFpi on l,25D3-stimulated alkaline phosphatase
activity. MG63 cells were treated with different doses of TGF(3i in the presence or
absence of 1,25D3 for 48 hours. The alkaline phosphatase activity was determined as
described in “Materials and Methods”. Data are expressed as mean ± SD of six
replicates. * P < 0.01 compared with the untreated control, a P < 0.05 compared with
the TGF(3i treatment alone.
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Figure 28. Time course of the TGFBi effect on l,25D3-stimulated alkaline phosphatase
mRNA level. This is a 36 hour time course study. 80% of subconfluent cells were
treated with 1 ng/ml TGFJBi, 10 ‘8 M 1,25D3, and the TGFBi plus 1,25D3. The total
RNA was isolated and 40 ug of total RNA was loaded on gel, transferred and hybridized
with a 40 mer oligodeoxynucleotide alkaline phosphatase probe. The upper panel shows
alkaline phosphatase mRNA bands and the lower panel shows methylene blue stained 28 S
rRNA to normalize RNA loading (Figure 28A). Lanes 1 to 4 are control (vehicle),
TGFBi at 1 ng/ml, 1,25D3 at 10 -8 M and the combination of TGFBi and 1,25D3
respectively. Figure 28B showed densitometry scan data from alkaline phosphatase
Northern blot. Each point represents the mean ± SD of at least two separate experiments.
** P < 0.01 compared with the untreated control.
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Figure 29. Time course of the effect of TGFPi and 1,25D3 on VDR mRNA level.
Subconfluent cells were treated with 1 ng/ml TGFPi, 10 '8 M 1,25D3, or the combination
of TGFBi plus 1,25D3. The total RNA was isolated at the time indicated and 20 (ig of
RNA was loaded on the gel, transferred to the membrane and blotted with a 600 bp long
VDR cDNA probe. VDR mRNA was shown on the upper panel and methylene blue
stained 28 S rRNA was shown at the lower panel to evaluate RNA loading. Lanes 1 to 4
are control, TGFBi, 1,25D3 and the combination of TGFBi and 1,25D3 respectively
(Figure 29A). Densitometry scanned results were shown on Figure 29B. Each point
represents the mean ± SD of at least two separate experiments. * P < 0.05 and
** P < 0.01 compared with the untreated control.
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Figure 30. Effect of the combination TGFBi with 1,25D3 on VDR protein level.
MG63 cells were treated with 1 ng/ml TGFBi and 10'8 M 1,25D3. The cell layer was
extracted at the indicated time and the nuclear protein was separated as described under
“ Material and Methods”. The nuclear proteins were subjected to SDS-PAGE, transferred
to nitrocellulose membranes, and immunoblotted with anti-hVDR antibodies. The bands
were detected by using the color-developing kit (BCIP and NBT kit). VDR protein
appears as a 55 kDa molecular mass band (Figure 30A). Densitometry scan data from at
least 2 experiments were used for statistical analysis (Figure 3OB). * P < 0.05 and
** P < 0.01 compared with the untreated control.
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Figure 31. Effect of TGF{3i, 1,25D3 and the combination of both TGFBi and 1,25D3 on
VDR phosphorylation. Cells were prelabeled with 0.5 mCi of [ 32P] orthophosphate for
two hours and then treated with ethanol vehicle (lane 1), 10 '8 M 1,25D3 (lane 2), 1 ng/ml
TGFPi (lane 3) and the combination (lane 4) for another two hours as described in
“Materials and Methods”. Cell lysates were immunoprecipitated with anti-hVDR
polyclonal antibodies and subjected to 12% SDS -PAGE. Figure 31 A. showed
autoradiogram of VDR phosphorylation and Figure 3 IB shows laser densitometry
scanned results from at least 3 experiments.
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Figure 32. Proposed model of TGFBi action on 1,25D3- stimulated alkaline
phosphatase activity in human MG63 osteosarcoma cells. See Chapter Four for details.
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